PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 33866035-6 2021 Furthermore, given the high affinity of alginate sulfate to heparin-binding growth factors, the sulfated IPN bioink supported the sustained release of transforming growth factor-beta3 (TGF-beta3), providing an environment that supported robust chondrogenesis in vitro, with little evidence of hypertrophy or mineralization over extended culture periods. ipn 105-108 transforming growth factor beta 3 Homo sapiens 151-183 33753316-0 2021 Nanofibrous Hyaluronic Acid Scaffolds Delivering TGF-beta3 and SDF-1alpha for Articular Cartilage Repair in a Large Animal Model. Hyaluronic Acid 12-27 transforming growth factor beta 3 Homo sapiens 49-58 33753316-10 2021 We have created a cell-free nanofibrous hyaluronic acid (HA) scaffold that delivers factors specifically designed to enhance cartilage repair: Stromal Cell-Derived Factor-1alpha (SDF-1alpha; SDF) to increase the recruitment and infiltration of mesenchymal stem cells (MSCs) and Transforming Growth Factor-beta3 (TGF-beta3; TGF) to enhance cartilage tissue formation. Hyaluronic Acid 57-59 transforming growth factor beta 3 Homo sapiens 278-310 33753316-10 2021 We have created a cell-free nanofibrous hyaluronic acid (HA) scaffold that delivers factors specifically designed to enhance cartilage repair: Stromal Cell-Derived Factor-1alpha (SDF-1alpha; SDF) to increase the recruitment and infiltration of mesenchymal stem cells (MSCs) and Transforming Growth Factor-beta3 (TGF-beta3; TGF) to enhance cartilage tissue formation. Hyaluronic Acid 57-59 transforming growth factor beta 3 Homo sapiens 312-321 33866035-6 2021 Furthermore, given the high affinity of alginate sulfate to heparin-binding growth factors, the sulfated IPN bioink supported the sustained release of transforming growth factor-beta3 (TGF-beta3), providing an environment that supported robust chondrogenesis in vitro, with little evidence of hypertrophy or mineralization over extended culture periods. ipn 105-108 transforming growth factor beta 3 Homo sapiens 185-194 33866035-11 2021 The presence of alginate sulfate provided the capacity of high affinity-binding of TGF-beta3, which promoted robust chondrogenesis. alginate sulfate 16-32 transforming growth factor beta 3 Homo sapiens 83-92 33827271-7 2021 In this vein, a heparin-conjugated mechanically-robust collagen fabric was developed for sustained delivery of TGF-beta3. Heparin 16-23 transforming growth factor beta 3 Homo sapiens 111-120 33827271-8 2021 The amount of conjugated heparin was varied to enhance the amount of TGF-beta3 uptake and release from the scaffold. Heparin 25-32 transforming growth factor beta 3 Homo sapiens 69-78 33827271-9 2021 The results showed that the scaffold delivered TGF-beta3 for up to 8 days of culture which resulted in 15-fold increase in GAG production, and 6-fold increase in collagen synthesis with respect to the No TGF-beta3 group. Glycosaminoglycans 123-126 transforming growth factor beta 3 Homo sapiens 47-56 33618224-10 2021 TGF-beta1 and/or TGF-beta3 inhibited myotube differentiation which was antagonized by LY364947. Ly-364947 86-94 transforming growth factor beta 3 Homo sapiens 17-26 33728344-9 2021 The levels of TGF-beta1 and TGF-beta3 in AH were positively associated with AL. Aluminum 76-78 transforming growth factor beta 3 Homo sapiens 28-37 32640500-4 2020 Transcriptome analysis of hPSCs derived hemogenic endothelial cells showed that ALA promoted endothelial-to-hematopoietic transition by up-regulating RUNX1, GFI1, GFI1B, MEIS2, and HIF1A and down-regulating SOX17, TGFB1, TGFB2, TGFB3, TGFBR1, and TGFBR2. Thioctic Acid 80-83 transforming growth factor beta 3 Homo sapiens 228-233 33565061-7 2021 In PA-MSCs, expression level of Twist1 and TGF-beta3 was the highest and FGF2 was the lowest. Protactinium 3-5 transforming growth factor beta 3 Homo sapiens 43-52 33565061-11 2021 The regulatory effect of Twist1, SIRT1, FGF2 and TGF-beta3 genes on PA-MSCs, UC-MSCs and DP-MSCs are different. Protactinium 68-70 transforming growth factor beta 3 Homo sapiens 49-58 33166613-6 2021 Here, we report the effects of AVID200, a potent TGFbeta1 and TGFbeta3 specific inhibitor, on FA hematopoiesis. avid200 31-38 transforming growth factor beta 3 Homo sapiens 62-70 32462800-8 2020 RESULT: Hematoxylin and eosin staining showed that cells in the TGF-beta3 group and the TK group had formed cartilage-like tissue after 21 days of culture. Hematoxylin 8-19 transforming growth factor beta 3 Homo sapiens 64-73 32652126-6 2020 Binding studies of TGFbeta3 and TbetaRII were carried out at different pH values and salt concentrations to gain further insight into the thermodynamics of the interaction. Salts 85-89 transforming growth factor beta 3 Homo sapiens 19-27 33115953-6 2020 When Ad-MKX-transduced MSCs were seeded on TGF-beta3-conjugated decellularized meniscus scaffold (DMS) and inserted into experimental tears in meniscus explants, they increased glycosaminoglycan content, extracellular matrix interconnectivity, cell infiltration into the DMS, and improved biomechanical properties. Glycosaminoglycans 177-194 transforming growth factor beta 3 Homo sapiens 43-52 32913927-3 2021 Connective tissue growth factor (CTGF) and transforming growth factor-beta3 (TGF-beta3) were loaded onto polydopamine nanoparticles, which were mixed with bone marrow mesenchymal stem cells (BMSCs) for regenerating and simulating the structure and function of the nucleus pulposus and annular fibrosus. polydopamine 105-117 transforming growth factor beta 3 Homo sapiens 77-86 33035696-0 2020 TGFbeta3 is Neuroprotective and Alleviates the Neurotoxic Response Induced by Aligned Poly-L-Lactic Acid Fibers on Naive and Activated Primary Astrocytes. poly(lactide) 86-104 transforming growth factor beta 3 Homo sapiens 0-8 32620316-6 2020 RESULTS: While UVB irradiation or SCF/ET-1 enhanced melanogenesis, TGF-beta3 effectively inhibited melanin accumulation and tyrosinase activity via downregulation of the extracellular signal-regulated kinase (ERK)/microphthalmia-associated transcription factor (MITF) pathway. Melanins 99-106 transforming growth factor beta 3 Homo sapiens 67-76 32462800-9 2020 The results of immunofluorescence and Alcian blue staining showed that compared with the control group, cells in the KGN and TGF-beta3 groups demonstrated increased secretion of aggrecan after 21 days of culture. Alcian Blue 38-49 transforming growth factor beta 3 Homo sapiens 125-134 32044676-0 2020 Sustained release of TGF-beta3 from polysaccharide nanoparticles induces chondrogenic differentiation of human mesenchymal stromal cells. Polysaccharides 36-50 transforming growth factor beta 3 Homo sapiens 21-30 32240810-2 2020 In order to develop such a system to support bone tissue regeneration, in the present study, we developed a three-dimensional poly(L-lactic-co-glycolic acid) (PLGA)/Polycaprolactone (PCL) nanohybrid scaffold embedded with PLGA macroparticles (MPs) conjugated with TGF-beta3 for the growth and chondrogenic differentiation of human mesenchymal stem cells (hMSCs). polycaprolactone 183-186 transforming growth factor beta 3 Homo sapiens 264-273 32044676-3 2020 Here we developed three innovative delivery systems based on different polysaccharides in order to induce a sustained release of TGF-beta3 to mediate chondrogenesis of human mesenchymal stromal cells. Polysaccharides 71-86 transforming growth factor beta 3 Homo sapiens 129-138 32204019-3 2020 In this study, we found the synergistic effects of kartogenin (KGN) and transforming growth factor beta3 (TGF-beta3) on chondrogenesis of MSCs in vitro, indicating that KGN and TGF-beta3 are a good match for cartilage regeneration. kartogenin 51-61 transforming growth factor beta 3 Homo sapiens 177-186 32204019-6 2020 When loaded with KGN conjugated polyurethane nanoparticles (PN-KGN) and TGF-beta3, this hydrogel showed biological functions by the release of KGN and TGF-beta3, which promoted the MSC migration and cartilage regeneration in one system. Polyurethanes 32-44 transforming growth factor beta 3 Homo sapiens 151-160 32351985-9 2020 However, overexpression of TGF-beta3 was associated with poor OS from the use of platins and poor PFS of Taxol or a platin+Taxol in women with ovarian carcinoma. platins 81-88 transforming growth factor beta 3 Homo sapiens 27-36 32351985-9 2020 However, overexpression of TGF-beta3 was associated with poor OS from the use of platins and poor PFS of Taxol or a platin+Taxol in women with ovarian carcinoma. Paclitaxel 105-110 transforming growth factor beta 3 Homo sapiens 27-36 32351985-9 2020 However, overexpression of TGF-beta3 was associated with poor OS from the use of platins and poor PFS of Taxol or a platin+Taxol in women with ovarian carcinoma. Platinum 81-87 transforming growth factor beta 3 Homo sapiens 27-36 32351985-9 2020 However, overexpression of TGF-beta3 was associated with poor OS from the use of platins and poor PFS of Taxol or a platin+Taxol in women with ovarian carcinoma. Paclitaxel 123-128 transforming growth factor beta 3 Homo sapiens 27-36 31945435-2 2020 TGFbeta3, expressed in inclusion bodies, is a classical example of a protein prone to high rate of aggregation severely limiting its refolding yield owing to its large cysteine content and structural complexity. Cysteine 168-176 transforming growth factor beta 3 Homo sapiens 0-8 31945435-7 2020 The effect of polyphenols on the aggregation kinetics and stability of native TGFbeta3 was also explored. Polyphenols 14-25 transforming growth factor beta 3 Homo sapiens 78-86 31739978-6 2020 MAIN OUTCOME MEASURE(S): Vitamin D effect in xenograft tissue was assessed by monitoring tumor size (18F-FDG positron-emission tomography/computerized tomography and macroscopic examination), cell proliferation (immunohistochemistry and quantitative real-time polymerase chain reaction [qRT-PCR]), ECM (Western blot), transforming growth factor (TGF) beta3 (qRT-PCR), and apoptosis (Westrn blot and TUNEL). Vitamin D 25-34 transforming growth factor beta 3 Homo sapiens 318-356 31826469-0 2020 Promoted chondrogenesis of hMCSs with controlled release of TGF-beta3 via microfluidics synthesized alginate nanogels. Alginates 100-108 transforming growth factor beta 3 Homo sapiens 60-69 31826469-3 2020 Here, we proposed an on-chip hydrodynamic flow focusing microfluidic approach for synthesis of alginate nanogels loaded with the transforming growth factor beta 3 (TGF-beta3) through an ionic gelation method in order to achieve precise release profile of these bioactive agents during chondrogenic differentiation of mesenchymal stem cells (MSCs). Alginates 95-103 transforming growth factor beta 3 Homo sapiens 129-162 31826469-3 2020 Here, we proposed an on-chip hydrodynamic flow focusing microfluidic approach for synthesis of alginate nanogels loaded with the transforming growth factor beta 3 (TGF-beta3) through an ionic gelation method in order to achieve precise release profile of these bioactive agents during chondrogenic differentiation of mesenchymal stem cells (MSCs). Alginates 95-103 transforming growth factor beta 3 Homo sapiens 164-173 32035282-4 2020 In this study, we have tested the incorporation of graphene oxide nanosheets (GO) within a photopolymerizable poly-D, L-lactic acid/polyethylene glycol (PDLLA) hydrogel, for its applicability in sustained release of the chondroinductive growth factor TGF-beta3. Graphite 51-65 transforming growth factor beta 3 Homo sapiens 251-260 32035282-10 2020 Statement of Significance In this work, we have developed a graphene oxide (GO) incorporated, photocrosslinked PDLLA hybrid hydrogel for localized delivery and sustained release of loaded TGF-beta3 to seeded cells. Graphite 60-74 transforming growth factor beta 3 Homo sapiens 188-197 31739978-11 2020 Similarly, long-term high-dose vitamin D significantly reduced TGF-beta3 expression. Vitamin D 31-40 transforming growth factor beta 3 Homo sapiens 63-72 30971109-3 2021 The objective of this study was to investigate whether preconditioning with hypoxia and/or transforming growth factor-beta 3 (TGF-beta3) can enhance MSC survival and extracellular matrix production in a low oxygen and nutrient-limited microenvironment. Oxygen 207-213 transforming growth factor beta 3 Homo sapiens 91-124 31325577-4 2019 This study utilized graphene oxide (GO) flakes to adsorb transforming growth factor beta3 (TGF-beta3), which were then incorporated into a collagen hydrogel. graphene oxide 20-34 transforming growth factor beta 3 Homo sapiens 57-89 31325577-4 2019 This study utilized graphene oxide (GO) flakes to adsorb transforming growth factor beta3 (TGF-beta3), which were then incorporated into a collagen hydrogel. graphene oxide 20-34 transforming growth factor beta 3 Homo sapiens 91-100 31325577-4 2019 This study utilized graphene oxide (GO) flakes to adsorb transforming growth factor beta3 (TGF-beta3), which were then incorporated into a collagen hydrogel. graphene oxide 36-38 transforming growth factor beta 3 Homo sapiens 57-89 31325577-4 2019 This study utilized graphene oxide (GO) flakes to adsorb transforming growth factor beta3 (TGF-beta3), which were then incorporated into a collagen hydrogel. graphene oxide 36-38 transforming growth factor beta 3 Homo sapiens 91-100 31325577-15 2019 Our study for the first time demonstrated simultaneously incorporating both human mesenchymal stem cells (hMSCs) and GO (graphene oxide)-adsorbed growth factor TGFbeta3 into a 3D scaffold, where GO-adsorbed TGFbeta3 enhanced chondrogenic differentiation of hMSCs and cartilage-tissue synthesis throughout the scaffold without needing to repeatedly supply TGFbeta3 exogenously. graphene oxide 121-135 transforming growth factor beta 3 Homo sapiens 160-168 31325577-15 2019 Our study for the first time demonstrated simultaneously incorporating both human mesenchymal stem cells (hMSCs) and GO (graphene oxide)-adsorbed growth factor TGFbeta3 into a 3D scaffold, where GO-adsorbed TGFbeta3 enhanced chondrogenic differentiation of hMSCs and cartilage-tissue synthesis throughout the scaffold without needing to repeatedly supply TGFbeta3 exogenously. graphene oxide 121-135 transforming growth factor beta 3 Homo sapiens 207-215 31325577-15 2019 Our study for the first time demonstrated simultaneously incorporating both human mesenchymal stem cells (hMSCs) and GO (graphene oxide)-adsorbed growth factor TGFbeta3 into a 3D scaffold, where GO-adsorbed TGFbeta3 enhanced chondrogenic differentiation of hMSCs and cartilage-tissue synthesis throughout the scaffold without needing to repeatedly supply TGFbeta3 exogenously. graphene oxide 121-135 transforming growth factor beta 3 Homo sapiens 207-215 30908692-6 2019 The release rate of TGFbeta3 was controlled by varying compositions of poly(lactic-co-glycolic acids) (PLGA) microspheres. Polylactic Acid-Polyglycolic Acid Copolymer 71-101 transforming growth factor beta 3 Homo sapiens 20-28 31737612-0 2019 Low-Molecular-Weight Heparin-Functionalized Chitosan-Chondroitin Sulfate Hydrogels for Controlled Release of TGF-beta3 and in vitro Neocartilage Formation. Sulfates 65-72 transforming growth factor beta 3 Homo sapiens 109-118 31737612-3 2019 In this study, we incorporated low-molecular-weight heparin (LMWH) into carboxymethyl chitosan-oxidized chondroitin sulfate (CMC-OCS) hydrogel for loading transforming growth factor-beta3 (TGF-beta3) as matrix of peripheral blood mesenchymal stem cells (PB-MSCs) to construct tissue-engineered cartilage. Heparin 52-59 transforming growth factor beta 3 Homo sapiens 155-187 31737612-3 2019 In this study, we incorporated low-molecular-weight heparin (LMWH) into carboxymethyl chitosan-oxidized chondroitin sulfate (CMC-OCS) hydrogel for loading transforming growth factor-beta3 (TGF-beta3) as matrix of peripheral blood mesenchymal stem cells (PB-MSCs) to construct tissue-engineered cartilage. Heparin 52-59 transforming growth factor beta 3 Homo sapiens 189-198 31737612-3 2019 In this study, we incorporated low-molecular-weight heparin (LMWH) into carboxymethyl chitosan-oxidized chondroitin sulfate (CMC-OCS) hydrogel for loading transforming growth factor-beta3 (TGF-beta3) as matrix of peripheral blood mesenchymal stem cells (PB-MSCs) to construct tissue-engineered cartilage. Sulfates 116-123 transforming growth factor beta 3 Homo sapiens 155-187 30971109-3 2021 The objective of this study was to investigate whether preconditioning with hypoxia and/or transforming growth factor-beta 3 (TGF-beta3) can enhance MSC survival and extracellular matrix production in a low oxygen and nutrient-limited microenvironment. Oxygen 207-213 transforming growth factor beta 3 Homo sapiens 126-135 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. poly-d 111-117 transforming growth factor beta 3 Homo sapiens 15-24 30871768-0 2019 Ulipristal acetate decreases active TGF-beta3 and its canonical signaling in uterine leiomyoma via two novel mechanisms. ulipristal acetate 0-18 transforming growth factor beta 3 Homo sapiens 36-45 30511964-6 2019 Functionally, FOXA1 downregulation induces TGF-beta signaling, EMT, and cell motility, which is effectively blocked by the TGF-beta receptor I inhibitor galunisertib (LY2157299). LY-2157299 153-165 transforming growth factor beta 3 Homo sapiens 43-51 30511964-6 2019 Functionally, FOXA1 downregulation induces TGF-beta signaling, EMT, and cell motility, which is effectively blocked by the TGF-beta receptor I inhibitor galunisertib (LY2157299). LY-2157299 167-176 transforming growth factor beta 3 Homo sapiens 43-51 30423434-3 2019 We have now expressed recombinant human TGF-beta3 in Escherichia coli Origami B (DE3), with yield 300 +- 17 mg/L monomeric protein at pilot scale. origami b 70-79 transforming growth factor beta 3 Homo sapiens 40-49 30825603-5 2019 In vivo, DMOG delivery significantly reduced mineralisation of the proteoglycan-rich cartilaginous tissue generated by MSCs within alginate hydrogels loaded with TGF-beta3 and BMP-2. oxalylglycine 9-13 transforming growth factor beta 3 Homo sapiens 162-171 30650248-0 2019 Effect of the small compound TD-198946 on glycosaminoglycan synthesis and transforming growth factor beta3-associated chondrogenesis of human synovium-derived stem cells in vitro. TD-198946 29-38 transforming growth factor beta 3 Homo sapiens 74-106 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. Lactic Acid 118-131 transforming growth factor beta 3 Homo sapiens 15-24 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. Polyethylene Glycols 132-151 transforming growth factor beta 3 Homo sapiens 15-24 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. poly(lactide) 111-131 transforming growth factor beta 3 Homo sapiens 15-24 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. pdlla-peg 174-183 transforming growth factor beta 3 Homo sapiens 15-24 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. pdlla-peg 198-207 transforming growth factor beta 3 Homo sapiens 15-24 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. Hyaluronic Acid 229-244 transforming growth factor beta 3 Homo sapiens 15-24 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. pdlla 174-179 transforming growth factor beta 3 Homo sapiens 15-24 30458242-3 2019 In this study, TGF-beta3 was directly loaded with human bone marrow-derived mesenchymal stem cells (MSCs) into poly-d,l-lactic acid/polyethylene glycol/poly-d,l-lactic acid (PDLLA-PEG) hydrogel, or PDLLA-PEG with the addition of hyaluronic acid (PDLLA/HA), and cultured in vitro. Hyaluronic Acid 252-254 transforming growth factor beta 3 Homo sapiens 15-24 30458242-11 2019 In this study, we demonstrated that incorporation of hyaluronic acid (HA) into a physiologically stiff PDLLA-PEG hydrogel allowed for slow release of one-time preloaded TGF-beta3, and when loaded with adult mesenchymal stem cells and cultured in vitro, it resulted in higher chondrogenic gene expression and constructs of significantly higher mechanical strength than constructs cultured in conventional TGF-beta3-supplemented medium. Hyaluronic Acid 53-68 transforming growth factor beta 3 Homo sapiens 169-178 30458242-11 2019 In this study, we demonstrated that incorporation of hyaluronic acid (HA) into a physiologically stiff PDLLA-PEG hydrogel allowed for slow release of one-time preloaded TGF-beta3, and when loaded with adult mesenchymal stem cells and cultured in vitro, it resulted in higher chondrogenic gene expression and constructs of significantly higher mechanical strength than constructs cultured in conventional TGF-beta3-supplemented medium. Hyaluronic Acid 53-68 transforming growth factor beta 3 Homo sapiens 404-413 30458242-11 2019 In this study, we demonstrated that incorporation of hyaluronic acid (HA) into a physiologically stiff PDLLA-PEG hydrogel allowed for slow release of one-time preloaded TGF-beta3, and when loaded with adult mesenchymal stem cells and cultured in vitro, it resulted in higher chondrogenic gene expression and constructs of significantly higher mechanical strength than constructs cultured in conventional TGF-beta3-supplemented medium. Hyaluronic Acid 70-72 transforming growth factor beta 3 Homo sapiens 169-178 30458242-11 2019 In this study, we demonstrated that incorporation of hyaluronic acid (HA) into a physiologically stiff PDLLA-PEG hydrogel allowed for slow release of one-time preloaded TGF-beta3, and when loaded with adult mesenchymal stem cells and cultured in vitro, it resulted in higher chondrogenic gene expression and constructs of significantly higher mechanical strength than constructs cultured in conventional TGF-beta3-supplemented medium. Hyaluronic Acid 70-72 transforming growth factor beta 3 Homo sapiens 404-413 30130672-13 2018 Furthermore, 20 muM of quercetin increases both mRNA and protein levels of TGF-beta3 under basal and wound conditions without affecting TGF-beta1 production. Quercetin 23-32 transforming growth factor beta 3 Homo sapiens 75-84 30033085-3 2018 Using a human induced pluripotent stem cell-derived liver bud (hiPSC-LB) model, we found hypoxia induced with an O2-permeable plate promoted hepatic differentiation accompanied by TGFB1 and TGFB3 suppression. Oxygen 113-115 transforming growth factor beta 3 Homo sapiens 190-195 30003432-9 2018 TGFbeta-2 was inversely correlated with glucose and low-density lipoprotein (LDL)-cholesterol, whereas TGF-beta3 was inversely correlated with the serum cholesterol concentration. Cholesterol 153-164 transforming growth factor beta 3 Homo sapiens 103-112 30158983-7 2018 An inhibitor of the TGF-beta signal, SB431542, not only inhibited TbetaRIII RNAi-stimulated TGF-beta3-mediated Smad2/3 phosphorylation but also inhibited the effects of TbetaRIII RNAi on TGF-beta3-induced chondrogenic differentiation. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 37-45 transforming growth factor beta 3 Homo sapiens 92-101 30158983-7 2018 An inhibitor of the TGF-beta signal, SB431542, not only inhibited TbetaRIII RNAi-stimulated TGF-beta3-mediated Smad2/3 phosphorylation but also inhibited the effects of TbetaRIII RNAi on TGF-beta3-induced chondrogenic differentiation. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 37-45 transforming growth factor beta 3 Homo sapiens 187-196 29705655-3 2018 Poly(ethylene glycol) (PEG) hydrogels were functionalized with TGFbeta3 or BMP-2, enzymatically polymerized encapsulating human BMSCs, combined with a hydrogel layer containing human NCs and ectopically implanted in nude mice without pre-culture. Polyethylene Glycols 0-21 transforming growth factor beta 3 Homo sapiens 63-71 29980690-2 2018 The objective of this research was to investigate the endogenous BMP7 expression in human osteoarthritis (OA) cartilage and the effect of oxygen tension on the single or combined treatment with TGF-beta3 and BMP7 on OA chondrocyte redifferentiation in three dimensional (3D) pellet cultures. Oxygen 138-144 transforming growth factor beta 3 Homo sapiens 194-203 29980690-8 2018 Our data underscores the important modulatory role of oxygen tension on the chondrocyte"s responsiveness to TGF-beta3 and/or BMP7. Oxygen 54-60 transforming growth factor beta 3 Homo sapiens 108-117 29705655-3 2018 Poly(ethylene glycol) (PEG) hydrogels were functionalized with TGFbeta3 or BMP-2, enzymatically polymerized encapsulating human BMSCs, combined with a hydrogel layer containing human NCs and ectopically implanted in nude mice without pre-culture. Polyethylene Glycols 23-26 transforming growth factor beta 3 Homo sapiens 63-71 29970676-0 2018 The effect of TGF-beta signaling on regulating proliferation of uterine leiomyoma cell via ERalpha signaling activated by bisphenol A, octylphenol and nonylphenol in vitro. bisphenol A 122-133 transforming growth factor beta 3 Homo sapiens 14-22 29943542-5 2018 Addition of 100 ng/mL IFN-beta1a to regular TGF-beta3 chondrogenic differentiation medium could improve the concentration of GAG, increase the size of pellets, promote the formation of aggrecan and up-regulate the expression of CollangenII and Sox9. Glycosaminoglycans 125-128 transforming growth factor beta 3 Homo sapiens 44-53 29970676-5 2018 Somehow, the expression of p-Smad3 and c-fos proteins significantly decreased in each of E2, bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP) group, as well as the expression of SnoN protein significantly reduced only in BPA and NP groups, followed by TGF-beta3 treatment. nonylphenol 112-123 transforming growth factor beta 3 Homo sapiens 261-270 29970676-5 2018 Somehow, the expression of p-Smad3 and c-fos proteins significantly decreased in each of E2, bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP) group, as well as the expression of SnoN protein significantly reduced only in BPA and NP groups, followed by TGF-beta3 treatment. nonylphenol 125-127 transforming growth factor beta 3 Homo sapiens 261-270 29970676-0 2018 The effect of TGF-beta signaling on regulating proliferation of uterine leiomyoma cell via ERalpha signaling activated by bisphenol A, octylphenol and nonylphenol in vitro. octylphenol 135-146 transforming growth factor beta 3 Homo sapiens 14-22 29970676-5 2018 Somehow, the expression of p-Smad3 and c-fos proteins significantly decreased in each of E2, bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP) group, as well as the expression of SnoN protein significantly reduced only in BPA and NP groups, followed by TGF-beta3 treatment. octylphenol 134-145 transforming growth factor beta 3 Homo sapiens 261-270 29970676-0 2018 The effect of TGF-beta signaling on regulating proliferation of uterine leiomyoma cell via ERalpha signaling activated by bisphenol A, octylphenol and nonylphenol in vitro. nonylphenol 151-162 transforming growth factor beta 3 Homo sapiens 14-22 29970676-5 2018 Somehow, the expression of p-Smad3 and c-fos proteins significantly decreased in each of E2, bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP) group, as well as the expression of SnoN protein significantly reduced only in BPA and NP groups, followed by TGF-beta3 treatment. bisphenol A 93-104 transforming growth factor beta 3 Homo sapiens 261-270 29970676-5 2018 Somehow, the expression of p-Smad3 and c-fos proteins significantly decreased in each of E2, bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP) group, as well as the expression of SnoN protein significantly reduced only in BPA and NP groups, followed by TGF-beta3 treatment. bisphenol A 106-109 transforming growth factor beta 3 Homo sapiens 261-270 29106040-4 2018 The temporal effect of transforming growth factor beta 3 (TGFbeta3) and fibroblast growth factor 2 (FGF2) on the derivation of proliferative chondrocytes from MSCs in three-dimensional agarose was investigated by manipulating the duration of TGFbeta3 and FGF2 treatment. Sepharose 185-192 transforming growth factor beta 3 Homo sapiens 23-56 29352392-3 2018 When hSMSCs-derived aggregates were cultured with TGFbeta3, dexamethasone up to 10 nM promoted chondrogenesis, but attenuated it with heterogeneous tissue formation when used at concentrations over than 100 nM. Dexamethasone 60-73 transforming growth factor beta 3 Homo sapiens 50-58 29352392-5 2018 In the presence of both TGFbeta3 and BMP2, dexamethasone dose dependently promoted cartilaginous tissue formation as judged by tissue volume, proteoglycan content, and type 2 collagen expression, whereas few adipocytes were detected in the formed tissue when cultures were supplemented with over 100 nM dexamethasone. Dexamethasone 43-56 transforming growth factor beta 3 Homo sapiens 24-32 29352392-5 2018 In the presence of both TGFbeta3 and BMP2, dexamethasone dose dependently promoted cartilaginous tissue formation as judged by tissue volume, proteoglycan content, and type 2 collagen expression, whereas few adipocytes were detected in the formed tissue when cultures were supplemented with over 100 nM dexamethasone. Dexamethasone 303-316 transforming growth factor beta 3 Homo sapiens 24-32 29178462-7 2018 Finally, when constructs were converted to Serum (in the continued presence of TGF-beta3 with or without dexamethasone) after pre-culture in CM+ for 4 weeks, GAG loss was attenuated with addition of dexamethasone. Dexamethasone 199-212 transforming growth factor beta 3 Homo sapiens 79-88 29106040-4 2018 The temporal effect of transforming growth factor beta 3 (TGFbeta3) and fibroblast growth factor 2 (FGF2) on the derivation of proliferative chondrocytes from MSCs in three-dimensional agarose was investigated by manipulating the duration of TGFbeta3 and FGF2 treatment. Sepharose 185-192 transforming growth factor beta 3 Homo sapiens 58-66 28161573-6 2017 Histological assessment of in vitro and subcutaneously implanted in vivo constructs demonstrated that CM-expanded cells followed by TGF-beta3 exposure resulted in highest cell proliferation, GAG accumulation, and collagen deposition. Glycosaminoglycans 191-194 transforming growth factor beta 3 Homo sapiens 132-141 29525690-0 2018 Ulipristal acetate decreases transforming growth factor beta3 serum and tumor tissue concentrations in patients with uterine fibroids. ulipristal acetate 0-18 transforming growth factor beta 3 Homo sapiens 29-61 27690373-10 2018 Increasing concentrations of the model protein lysozyme and transforming growth factor-beta3 were detected on scaffolds with increasing concentrations of NaCS (p < 0.05). nacs 154-158 transforming growth factor beta 3 Homo sapiens 60-92 28899816-6 2017 We also prepare multi-shell nanoparticles in different layers with a calcium phosphate core and DNA/calcium phosphate shells conjugated with polyethyleneimine to act as non-viral vectors for delivery of plasmid DNA encoding BMP2 and TGF-beta3, respectively. aziridine 141-158 transforming growth factor beta 3 Homo sapiens 233-242 28377490-6 2017 Inhibition of TGF-beta3 mRNA expression by ISTH2020 or ISTH2023, two different isoform-specific phosphorothioate locked nucleic acid (LNA)-modified antisense oligonucleotide gapmers, blocks downstream SMAD2 and SMAD1/5 phosphorylation in human LN-308 cells, without affecting TGF-beta1 or TGF-beta2 mRNA expression or protein levels. Parathion 96-112 transforming growth factor beta 3 Homo sapiens 14-23 28377490-6 2017 Inhibition of TGF-beta3 mRNA expression by ISTH2020 or ISTH2023, two different isoform-specific phosphorothioate locked nucleic acid (LNA)-modified antisense oligonucleotide gapmers, blocks downstream SMAD2 and SMAD1/5 phosphorylation in human LN-308 cells, without affecting TGF-beta1 or TGF-beta2 mRNA expression or protein levels. Oligonucleotides 158-173 transforming growth factor beta 3 Homo sapiens 14-23 29531934-5 2018 Results: The results showed ICA, TGFbeta3, and TGFbeta3 + ICA increased the rate of proliferation and viability of cells; but there were no significant differences between them (P > 0.05). icariin 58-61 transforming growth factor beta 3 Homo sapiens 47-55 29531934-7 2018 Furthermore, the results of the expression of type I and X collagens revealed that TGFbeta3 increased the expression of them (P < 0.01); However, treatment with ICA + TGFbeta3 down regulated the expression of these genes significantly. icariin 164-167 transforming growth factor beta 3 Homo sapiens 83-91 29531934-7 2018 Furthermore, the results of the expression of type I and X collagens revealed that TGFbeta3 increased the expression of them (P < 0.01); However, treatment with ICA + TGFbeta3 down regulated the expression of these genes significantly. icariin 164-167 transforming growth factor beta 3 Homo sapiens 170-178 28865136-4 2017 Here, we used polymer brushes as selective linkers of bone morphogenetic protein-2 (BMP-2) and transforming growth factor-beta3 (TGF-beta3) on the surface of 3D scaffolds fabricated via additive manufacturing (AM) and subsequent controlled radical polymerization. polymer brushes 14-29 transforming growth factor beta 3 Homo sapiens 95-127 28865136-4 2017 Here, we used polymer brushes as selective linkers of bone morphogenetic protein-2 (BMP-2) and transforming growth factor-beta3 (TGF-beta3) on the surface of 3D scaffolds fabricated via additive manufacturing (AM) and subsequent controlled radical polymerization. polymer brushes 14-29 transforming growth factor beta 3 Homo sapiens 129-138 28865136-6 2017 BMP-2 and TGF-beta3 were covalently bound both homogeneously within a poly(ethylene glycol) (PEG)-based brush-functionalized scaffolds, and following a gradient composition by varying their concentration along the axial section of the 3D constructs. Polyethylene Glycols 70-91 transforming growth factor beta 3 Homo sapiens 10-19 28865136-6 2017 BMP-2 and TGF-beta3 were covalently bound both homogeneously within a poly(ethylene glycol) (PEG)-based brush-functionalized scaffolds, and following a gradient composition by varying their concentration along the axial section of the 3D constructs. Polyethylene Glycols 93-96 transforming growth factor beta 3 Homo sapiens 10-19 28087378-6 2017 The scaffolds were prepared from poly(lactic-co-glycolic acid), and BMP-7/TGF-beta3 were loaded as nanocomplexes with heparin and Tetronic 1107. Heparin 118-125 transforming growth factor beta 3 Homo sapiens 74-83 28161573-10 2017 In this manuscript, we investigated the effects of conditioned medium (CM) and transforming growth factor-beta3 (TGF-beta3) on tonsil-derived mesenchymal stem cells (T-MSCs) encapsulated in riboflavin-induced photocrosslinked collagen-hyaluronic acid (COL-RF-HA) hydrogel. Riboflavin 190-200 transforming growth factor beta 3 Homo sapiens 113-122 28330503-13 2017 While dexamethasone or caffeine treatment did not affect TGF-beta1 mRNA in H441 cells, increased expression of TGF-beta2 and TGF-beta3 mRNA was detected upon exposure to dexamethasone or dexamethasone and caffeine, respectively. Dexamethasone 170-183 transforming growth factor beta 3 Homo sapiens 125-134 25690385-5 2017 We hypothesized that human DAP-derived MSCs (hSCAPs) can produce and secrete TGFbeta3 in response to micro-environmental cues. dap 27-30 transforming growth factor beta 3 Homo sapiens 77-85 28330503-13 2017 While dexamethasone or caffeine treatment did not affect TGF-beta1 mRNA in H441 cells, increased expression of TGF-beta2 and TGF-beta3 mRNA was detected upon exposure to dexamethasone or dexamethasone and caffeine, respectively. Dexamethasone 170-183 transforming growth factor beta 3 Homo sapiens 125-134 28330503-13 2017 While dexamethasone or caffeine treatment did not affect TGF-beta1 mRNA in H441 cells, increased expression of TGF-beta2 and TGF-beta3 mRNA was detected upon exposure to dexamethasone or dexamethasone and caffeine, respectively. Caffeine 205-213 transforming growth factor beta 3 Homo sapiens 125-134 30603496-9 2017 Col10A1, TGF-beta3, and SOX9 decreased significantly by 10-fold, 2.1-fold, and 3.2-fold respectively in TSA-treated pellets compared with those in untreated pellets, whereas expression of BMP4 and FGFR3 increased significantly by 2.1-fold and 5.4-fold respectively. trichostatin A 104-107 transforming growth factor beta 3 Homo sapiens 9-18 28231275-5 2017 For fibrosis inhibition we focused on the small molecule pirfenidone, which has been shown to prevent pulmonary fibrosis by the decrease of the expression of TGF-beta1, TGF-beta2 and TGF-beta3 cytokines. pirfenidone 57-68 transforming growth factor beta 3 Homo sapiens 183-192 27079852-0 2016 Gene Delivery of TGF-beta3 and BMP2 in an MSC-Laden Alginate Hydrogel for Articular Cartilage and Endochondral Bone Tissue Engineering. Alginates 52-60 transforming growth factor beta 3 Homo sapiens 17-26 26990273-1 2016 TGF-beta3 is enzymatically immobilized by transglutaminase-2 action to poly(l-lactic acid) microparticles coated with collagen II. poly(lactide) 71-90 transforming growth factor beta 3 Homo sapiens 0-9 27149081-0 2016 TGF-beta3-induced miR-494 inhibits macrophage polarization via suppressing PGE2 secretion in mesenchymal stem cells. Dinoprostone 75-79 transforming growth factor beta 3 Homo sapiens 0-9 27149081-8 2016 In summary, our findings suggest that the high expression of TGF-beta3 in PE decidua stimulates miR-494 in dMSCs and attenuates the regulation of MSC switching the macrophage toward M2 type, contributing to an immune imbalance at maternal-fetal interface. dmscs 107-112 transforming growth factor beta 3 Homo sapiens 61-70 27232667-5 2016 BMP-2 and dexamethasone in combination with TGF-beta1 or TGF-beta3 excelled at inducing chondrogenesis on SMSCs, HFPSCs and chondrocytes, as measured by glycosaminoglycans and collagen type II staining of pellets, quantitative glycosaminoglycan expression, quantitative PCR of cartilage signature genes and electron microscopy. Glycosaminoglycans 153-171 transforming growth factor beta 3 Homo sapiens 57-66 27232667-5 2016 BMP-2 and dexamethasone in combination with TGF-beta1 or TGF-beta3 excelled at inducing chondrogenesis on SMSCs, HFPSCs and chondrocytes, as measured by glycosaminoglycans and collagen type II staining of pellets, quantitative glycosaminoglycan expression, quantitative PCR of cartilage signature genes and electron microscopy. Glycosaminoglycans 153-170 transforming growth factor beta 3 Homo sapiens 57-66 26945456-8 2016 When MSCs seeded onto PAM-T were injected early after OA induction, protection of cartilage against degradation was evidenced and this effect was associated to a higher survival of MSCs in presence of TGFbeta3. pam-t 22-27 transforming growth factor beta 3 Homo sapiens 201-209 28372298-9 2017 The chondrogenic differentiation grade of hWJ-MSCs induced by TGFbeta3 was assessed by the Sirius red and Alcian blue staining. C.I. direct red 80 91-101 transforming growth factor beta 3 Homo sapiens 62-70 28372298-9 2017 The chondrogenic differentiation grade of hWJ-MSCs induced by TGFbeta3 was assessed by the Sirius red and Alcian blue staining. Alcian Blue 106-117 transforming growth factor beta 3 Homo sapiens 62-70 27079852-7 2016 Gene delivery of TGF-beta3 and BMP2 and subsequent cell-mediated expression of these therapeutic genes resulted in a significant increase in sulfated glycosaminoglycan and collagen production, particularly in the pTGF-beta3-pBMP2 codelivery group in comparison to the delivery of either pTGF-beta3 or pBMP2 in isolation. Glycosaminoglycans 150-167 transforming growth factor beta 3 Homo sapiens 17-26 27079852-10 2016 Together, these results suggest that the developed gene-activated alginate hydrogels were able to support transfection of encapsulated MSCs and directed their phenotype toward either a chondrogenic or an osteogenic phenotype depending on whether TGF-beta3 and BMP2 were delivered in combination or isolation. Alginates 66-74 transforming growth factor beta 3 Homo sapiens 246-255 26866713-6 2016 Similarly, the insulin/TGF-beta3-treated group presented a significant decrease in the deposition of cartilage matrix as detected by safranin O staining of histological sections of hBMSC micromass cultures when compared to the group stimulated with insulin alone. phenosafranine 133-143 transforming growth factor beta 3 Homo sapiens 23-32 27774108-3 2016 The purpose of this study was to construct poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles as carriers for TGF-beta3 controlled release and establish a codelivery system of a dextran/gelatin hydrogel with the nanoparticles for long-term processing of discogenesis differentiation. Polylactic Acid-Polyglycolic Acid Copolymer 43-73 transforming growth factor beta 3 Homo sapiens 111-120 27005024-0 2015 TGF-beta3 encapsulated PLCL scaffold by supercritical CO2-HFIP co-solvent system for cartilage tissue engineering. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 54-57 transforming growth factor beta 3 Homo sapiens 0-9 26608985-8 2015 Dynamic real-time polymerase chain reaction assay, ELISA and Western blotting from patient"s peripheral blood mononuclear cells and plasma were used to detect the expression of transforming growth factor beta 3 (TGF-beta3) messenger RNA (mRNA) and vascular endothelial growth factor (VEGF) protein before and after 6 months of thalidomide treatment. Thalidomide 327-338 transforming growth factor beta 3 Homo sapiens 177-210 26608985-11 2015 The Fli-EGFP zebrafish model manifested discontinuous vessel development and vascular occlusion (7 of 10 fishes), and the TGF-beta3 mRNA expression of five patients was lower after thalidomide therapy. Thalidomide 181-192 transforming growth factor beta 3 Homo sapiens 122-131 26608985-13 2015 CONCLUSIONS: Thalidomide reverses telangiectasia and controls nosebleeds by down-regulating the expression of TGF-beta3 and VEGF in HHT patients. Thalidomide 13-24 transforming growth factor beta 3 Homo sapiens 110-119 26783399-0 2016 Exogenous Heparan Sulfate Enhances the TGF-beta3-Induced Chondrogenesis in Human Mesenchymal Stem Cells by Activating TGF-beta/Smad Signaling. Heparitin Sulfate 10-25 transforming growth factor beta 3 Homo sapiens 39-48 26783399-5 2016 However, the combined TGF-beta3/HS treatment resulted in a significant increase in GAG synthesis, cartilage matrix protein secretion, and cartilage-specific gene expression compared to cells treated with TGF-beta3 alone. Glycosaminoglycans 83-86 transforming growth factor beta 3 Homo sapiens 22-31 26783399-7 2016 The inhibitor of the TGF-beta/Smad signal, SB431542, not only completely inhibited HS-stimulated TGF-beta3-mediated Smad2/3 phosphorylation but also completely inhibited the effects of HS on TGF-beta3-induced chondrogenic differentiation. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 43-51 transforming growth factor beta 3 Homo sapiens 97-106 26783399-7 2016 The inhibitor of the TGF-beta/Smad signal, SB431542, not only completely inhibited HS-stimulated TGF-beta3-mediated Smad2/3 phosphorylation but also completely inhibited the effects of HS on TGF-beta3-induced chondrogenic differentiation. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 43-51 transforming growth factor beta 3 Homo sapiens 191-200 25376622-9 2015 In vitro, we observed that alginate-collagen porous scaffolds supported cell proliferation and extracellular matrix deposition (collagen type I), with secretion amplified by the local release of transforming growth factor-beta3. Alginates 27-35 transforming growth factor beta 3 Homo sapiens 195-227 26347860-8 2015 The TGF-beta3 group also produced a collagen type II and glycosaminoglycan-rich extracellular matrix, detected by immunohistochemistry, Alcian blue staining, and Safranin O staining suggesting robust chondrogenesis within the scaffold. Glycosaminoglycans 57-74 transforming growth factor beta 3 Homo sapiens 4-13 26347860-8 2015 The TGF-beta3 group also produced a collagen type II and glycosaminoglycan-rich extracellular matrix, detected by immunohistochemistry, Alcian blue staining, and Safranin O staining suggesting robust chondrogenesis within the scaffold. Alcian Blue 136-147 transforming growth factor beta 3 Homo sapiens 4-13 26347860-8 2015 The TGF-beta3 group also produced a collagen type II and glycosaminoglycan-rich extracellular matrix, detected by immunohistochemistry, Alcian blue staining, and Safranin O staining suggesting robust chondrogenesis within the scaffold. phenosafranine 162-172 transforming growth factor beta 3 Homo sapiens 4-13 25800862-0 2015 Incorporation of TGF-beta 3 within collagen-hyaluronic acid scaffolds improves their chondrogenic potential. Hyaluronic Acid 44-59 transforming growth factor beta 3 Homo sapiens 17-27 25384834-0 2015 Duration of TGF-beta3 Exposure Impacts the Chondrogenic Maturation of Human MSCs in Photocrosslinked Carboxymethylcellulose Hydrogels. Carboxymethylcellulose Sodium 101-123 transforming growth factor beta 3 Homo sapiens 12-21 25384834-4 2015 Recently, photocrosslinked carboxymethylcellulose (CMC) hydrogels were shown to support chondrogenic, NP-like extracellular matrix (ECM) elaboration by human mesenchymal stromal cells (hMSCs) when supplemented with TGF-beta3. Carboxymethylcellulose Sodium 27-49 transforming growth factor beta 3 Homo sapiens 215-224 25384834-4 2015 Recently, photocrosslinked carboxymethylcellulose (CMC) hydrogels were shown to support chondrogenic, NP-like extracellular matrix (ECM) elaboration by human mesenchymal stromal cells (hMSCs) when supplemented with TGF-beta3. Carboxymethylcellulose Sodium 51-54 transforming growth factor beta 3 Homo sapiens 215-224 25384834-7 2015 The objective of this study was to evaluate the influence of TGF-beta3 exposure time on hydrogel bulk properties and NP-like matrix elaboration in hMSC-laden CMC hydrogels. Carboxymethylcellulose Sodium 158-161 transforming growth factor beta 3 Homo sapiens 61-70 25384834-16 2015 Overall, these findings support the use of short-term TGF-beta3 treatment to promote sufficient long-term tissue maturation in vitro in this hMSC-laden CMC hydrogel system. Carboxymethylcellulose Sodium 152-155 transforming growth factor beta 3 Homo sapiens 54-63 25853898-4 2015 Placental ceramides were elevated due to greater de novo synthesis via high serine palmitoyltransferase activity and reduced lysosomal breakdown via diminished ASAH1 expression caused by TGFB3-induced E2F4 transcriptional repression. Ceramides 10-19 transforming growth factor beta 3 Homo sapiens 187-192 25753754-0 2015 Fluocinolone Acetonide Is a Potent Synergistic Factor of TGF-beta3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration. Fluocinolone Acetonide 0-22 transforming growth factor beta 3 Homo sapiens 57-66 25866187-6 2015 Furthermore, the EMT polysaccharides support the loading and release of the chondroinduction factor transforming growth factor beta3 (TGF-beta3). Polysaccharides 21-36 transforming growth factor beta 3 Homo sapiens 100-132 25866187-6 2015 Furthermore, the EMT polysaccharides support the loading and release of the chondroinduction factor transforming growth factor beta3 (TGF-beta3). Polysaccharides 21-36 transforming growth factor beta 3 Homo sapiens 134-143 25804870-0 2015 TGF-beta3 encapsulated PLCL scaffold by a supercritical CO2-HFIP co-solvent system for cartilage tissue engineering. Carbon Dioxide 56-59 transforming growth factor beta 3 Homo sapiens 0-9 25695838-3 2015 We herein demonstrate that LAG3(+) Treg produce high amounts of TGF-beta3 in an Egr2- and Fas-dependent manner. ammonium ferrous sulfate 90-93 transforming growth factor beta 3 Homo sapiens 64-73 25647182-6 2015 MEASUREMENTS AND MAIN RESULTS: We found that human PASMC (HPASMC) from patients with PAH expressed decreased levels of the miR-17~92 cluster, TGF-beta, and SMC markers. pasmc 51-56 transforming growth factor beta 3 Homo sapiens 142-150 25315023-7 2015 TGF-beta3 supplementation led to a substantial increase in cartilage matrix depositions in all groups, but had differential effects on OAC-ADSC interactions in different co-culture models. SDZ 33-243 135-138 transforming growth factor beta 3 Homo sapiens 0-9 25543823-8 2014 Remarkably, over the 21 days of cultivation, HA + TGF-beta3 adsorbed scaffolds promoted the extracellular matrix molecules production with higher accumulation of HA (1.2 fold), collagen (1.42 fold) and uronic acid (1.41 fold). Uronic Acids 202-213 transforming growth factor beta 3 Homo sapiens 50-59 25670950-5 2015 RESULTS: Treatment with venlafaxine decreased expression of prolyl 4-hydroxylase (P4HB), ubiquitin-conjugating enzyme E2K (HIP2) and plastin 3 (T-plastin), and up-regulated expression of growth factor beta-3 (TGF-beta3), dihydropyrimidinase-like 3 (DPYSL3), and pyruvate kinase (PKM) after differentiation for 1 and 7 days. Venlafaxine Hydrochloride 24-35 transforming growth factor beta 3 Homo sapiens 209-218 25092545-3 2014 Recently, photocrosslinked carboxymethylcellulose (CMC) hydrogels were shown to support chondrogenic, NP-like extracellular matrix (ECM) elaboration by human mesenchymal stromal cells (hMSCs) when supplemented with TGF-beta3; however, mechanical properties of these constructs did not reach native values. Carboxymethylcellulose Sodium 27-49 transforming growth factor beta 3 Homo sapiens 215-224 25169425-0 2014 Initial boost release of transforming growth factor-beta3 and chondrogenesis by freeze-dried bioactive polymer scaffolds. Polymers 103-110 transforming growth factor beta 3 Homo sapiens 25-57 25169425-2 2014 Our aim was to analyze the chondrogenic potential of freeze-dried resorbable polymer-based polyglycolic acid (PGA) scaffolds bio-activated with transforming growth factor-beta3 (TGFB3) on human subchondral mesenchymal progenitor cells known from microfracture. polymer-based polyglycolic acid 77-108 transforming growth factor beta 3 Homo sapiens 144-176 25169425-2 2014 Our aim was to analyze the chondrogenic potential of freeze-dried resorbable polymer-based polyglycolic acid (PGA) scaffolds bio-activated with transforming growth factor-beta3 (TGFB3) on human subchondral mesenchymal progenitor cells known from microfracture. polymer-based polyglycolic acid 77-108 transforming growth factor beta 3 Homo sapiens 178-183 25169425-2 2014 Our aim was to analyze the chondrogenic potential of freeze-dried resorbable polymer-based polyglycolic acid (PGA) scaffolds bio-activated with transforming growth factor-beta3 (TGFB3) on human subchondral mesenchymal progenitor cells known from microfracture. Polyglycolic Acid 110-113 transforming growth factor beta 3 Homo sapiens 144-176 25169425-2 2014 Our aim was to analyze the chondrogenic potential of freeze-dried resorbable polymer-based polyglycolic acid (PGA) scaffolds bio-activated with transforming growth factor-beta3 (TGFB3) on human subchondral mesenchymal progenitor cells known from microfracture. Polyglycolic Acid 110-113 transforming growth factor beta 3 Homo sapiens 178-183 25169425-3 2014 Progenitor cells derived from femur heads were cultured in the presence of freeze-dried TGFB3 in high-density pellet culture and in freeze-dried TGFB3-PGA scaffolds for chondrogenic differentiation. Polyglycolic Acid 151-154 transforming growth factor beta 3 Homo sapiens 145-150 25169425-5 2014 Release studies showed that freeze-dried TGFB3-PGA scaffolds facilitate a rapid, initial boost-like release of 71.5% of TGFB3 in the first 10 h. Gene expression analysis and histology showed induction of typical chondrogenic markers like type II collagen and formation of cartilaginous tissue in TGFB3-PGA scaffolds seeded with subchondral progenitor cells and in pellet cultures stimulated with freeze-dried TGFB3. Polyglycolic Acid 46-50 transforming growth factor beta 3 Homo sapiens 120-125 25169425-5 2014 Release studies showed that freeze-dried TGFB3-PGA scaffolds facilitate a rapid, initial boost-like release of 71.5% of TGFB3 in the first 10 h. Gene expression analysis and histology showed induction of typical chondrogenic markers like type II collagen and formation of cartilaginous tissue in TGFB3-PGA scaffolds seeded with subchondral progenitor cells and in pellet cultures stimulated with freeze-dried TGFB3. Polyglycolic Acid 46-50 transforming growth factor beta 3 Homo sapiens 120-125 25169425-5 2014 Release studies showed that freeze-dried TGFB3-PGA scaffolds facilitate a rapid, initial boost-like release of 71.5% of TGFB3 in the first 10 h. Gene expression analysis and histology showed induction of typical chondrogenic markers like type II collagen and formation of cartilaginous tissue in TGFB3-PGA scaffolds seeded with subchondral progenitor cells and in pellet cultures stimulated with freeze-dried TGFB3. Polyglycolic Acid 46-50 transforming growth factor beta 3 Homo sapiens 120-125 25169425-5 2014 Release studies showed that freeze-dried TGFB3-PGA scaffolds facilitate a rapid, initial boost-like release of 71.5% of TGFB3 in the first 10 h. Gene expression analysis and histology showed induction of typical chondrogenic markers like type II collagen and formation of cartilaginous tissue in TGFB3-PGA scaffolds seeded with subchondral progenitor cells and in pellet cultures stimulated with freeze-dried TGFB3. Polyglycolic Acid 301-305 transforming growth factor beta 3 Homo sapiens 41-46 25169425-7 2014 These results suggest that bio-activated, freeze-dried TGFB3-PGA scaffolds have chondrogenic potential and are a promising tool for stem cell-mediated cartilage regeneration. Polyglycolic Acid 61-64 transforming growth factor beta 3 Homo sapiens 55-60 25092545-3 2014 Recently, photocrosslinked carboxymethylcellulose (CMC) hydrogels were shown to support chondrogenic, NP-like extracellular matrix (ECM) elaboration by human mesenchymal stromal cells (hMSCs) when supplemented with TGF-beta3; however, mechanical properties of these constructs did not reach native values. Carboxymethylcellulose Sodium 51-54 transforming growth factor beta 3 Homo sapiens 215-224 24768749-8 2014 Treated IVDs were injected with 0.2 mug TGFbeta3 in 20 muL phosphate-buffered saline+bovine serum albumin into several locations of the discectomy site. Phosphate-Buffered Saline 59-84 transforming growth factor beta 3 Homo sapiens 40-48 24712489-3 2014 We found that TGFbeta-driven chondrogenic differentiation of hMSCs cultured onto a hyaluronan-based scaffold, HYAFF( )-11, was strengthened after cell exposure to siRNA against Slug. Hyaluronic Acid 83-93 transforming growth factor beta 3 Homo sapiens 14-21 24712489-5 2014 In addition, we confirmed that HYAFF-11 is a good scaffold candidate for hMSC use in tissue engineering applications, and showed that it is effective in sustaining TGFbeta3 treatment associated with a specific gene silencing. hyaluronic acid benzyl ester 31-39 transforming growth factor beta 3 Homo sapiens 164-172 25022965-8 2014 The wound healing results indicated that TGF-beta3 has a significant effect on the wound healing process and its healing rate was found to be higher than the control (p < 0.001), TGF-beta1 (p < 0.001), TGF-beta2 (p < 0.001), BSA/HCl (p < 0.001) and HCl (p < 0.001) in ascending order. Hydrochloric Acid 238-241 transforming growth factor beta 3 Homo sapiens 41-50 24491910-7 2014 Enhanced accumulation of cartilage-associated glycosaminoglycans by hMSCs incubated with TGF-beta3-loaded microspheres was seen and positive staining for collagen type II and proteoglycan confirmed successful in vitro chondrogenesis. Glycosaminoglycans 46-64 transforming growth factor beta 3 Homo sapiens 89-98 24825427-0 2014 Liarozole inhibits transforming growth factor-beta3--mediated extracellular matrix formation in human three-dimensional leiomyoma cultures. liarozole 0-9 transforming growth factor beta 3 Homo sapiens 19-51 24825427-1 2014 OBJECTIVE: To investigate the impact of liarozole on transforming growth factor-beta3 (TGF-beta3) expression, TGF-beta3 controlled profibrotic cytokines, and extracellular matrix formation in a three-dimensional (3D) leiomyoma model system. liarozole 40-49 transforming growth factor beta 3 Homo sapiens 53-85 24825427-1 2014 OBJECTIVE: To investigate the impact of liarozole on transforming growth factor-beta3 (TGF-beta3) expression, TGF-beta3 controlled profibrotic cytokines, and extracellular matrix formation in a three-dimensional (3D) leiomyoma model system. liarozole 40-49 transforming growth factor beta 3 Homo sapiens 87-96 24825427-6 2014 MAIN OUTCOME MEASURE(S): Quantitative real-time reverse-transcriptase polymerase chain reaction and Western blotting to assess fold gene and protein expression of TGF-beta3 and TGF-beta3 regulated fibrotic cytokines: collagen 1A1 (COL1A1), fibronectin, and versican before and after treatment with liarozole, and confirmatory immunohistochemical stains of treated three-dimensional cultures. liarozole 298-307 transforming growth factor beta 3 Homo sapiens 163-172 24825427-6 2014 MAIN OUTCOME MEASURE(S): Quantitative real-time reverse-transcriptase polymerase chain reaction and Western blotting to assess fold gene and protein expression of TGF-beta3 and TGF-beta3 regulated fibrotic cytokines: collagen 1A1 (COL1A1), fibronectin, and versican before and after treatment with liarozole, and confirmatory immunohistochemical stains of treated three-dimensional cultures. liarozole 298-307 transforming growth factor beta 3 Homo sapiens 177-186 24825427-8 2014 Treatment with liarozole decreased TGF-beta3 gene and protein expression. liarozole 15-24 transforming growth factor beta 3 Homo sapiens 35-44 24825427-11 2014 CONCLUSION(S): Liarozole decreased TGF-beta3 and TGF-beta3-mediated extracellular matrix expression in a 3D uterine leiomyoma culture system. liarozole 15-24 transforming growth factor beta 3 Homo sapiens 35-44 24825427-11 2014 CONCLUSION(S): Liarozole decreased TGF-beta3 and TGF-beta3-mediated extracellular matrix expression in a 3D uterine leiomyoma culture system. liarozole 15-24 transforming growth factor beta 3 Homo sapiens 49-58 24284199-4 2014 TGF-beta3"s influences on pyridinoline content and mechanical properties were also measured. pyridinoline 26-38 transforming growth factor beta 3 Homo sapiens 0-9 24284199-8 2014 Transient TGF-beta3 produced the highest GAG synthesis rate, highest GAG retention ratio, and the highest binding affinity; collagen synthesis was elevated in TGF-beta3 supplementation groups over control, with the highest binding affinity observed in the transient supplementation group; both COMP synthesis and retention were lower than those for GAG and collagen. Glycosaminoglycans 41-44 transforming growth factor beta 3 Homo sapiens 10-19 24284199-8 2014 Transient TGF-beta3 produced the highest GAG synthesis rate, highest GAG retention ratio, and the highest binding affinity; collagen synthesis was elevated in TGF-beta3 supplementation groups over control, with the highest binding affinity observed in the transient supplementation group; both COMP synthesis and retention were lower than those for GAG and collagen. Glycosaminoglycans 69-72 transforming growth factor beta 3 Homo sapiens 10-19 24284199-8 2014 Transient TGF-beta3 produced the highest GAG synthesis rate, highest GAG retention ratio, and the highest binding affinity; collagen synthesis was elevated in TGF-beta3 supplementation groups over control, with the highest binding affinity observed in the transient supplementation group; both COMP synthesis and retention were lower than those for GAG and collagen. Glycosaminoglycans 69-72 transforming growth factor beta 3 Homo sapiens 10-19 24661914-9 2014 Isoflurane could activate HIF-1alpha, and the overexpression HIF-1alpha up-regulated the level of VEGF and TGF-beta3, VEGF decreased the expression of occludin and TGF-beta3 accelerated the endocytosis of occludin. Isoflurane 0-10 transforming growth factor beta 3 Homo sapiens 164-173 24650070-12 2014 TGF-beta3 activation seems to be induced by low dose-rate irradiation by a mechanism involving inducible nitric oxide (iNOS) and peroxynitrite, or during cycling hypoxia by a mechanism most likely involving HIF-1. Nitric Oxide 105-117 transforming growth factor beta 3 Homo sapiens 0-9 24650070-12 2014 TGF-beta3 activation seems to be induced by low dose-rate irradiation by a mechanism involving inducible nitric oxide (iNOS) and peroxynitrite, or during cycling hypoxia by a mechanism most likely involving HIF-1. Peroxynitrous Acid 129-142 transforming growth factor beta 3 Homo sapiens 0-9 23892982-3 2013 TGF-beta3 is irreversibly cross-linked by TG2 to collagen type II-coated poly(L-lactic acid) nanofibrous scaffolds and activates Smad phosphorylation and Smad-dependent expression of a luciferase reporter. poly(lactide) 73-92 transforming growth factor beta 3 Homo sapiens 0-9 24605794-4 2014 In addition, the differentiation of hMSCs was temporally controlled by changing the release profiles of transforming growth factor-beta3 (TGF-beta3) and/or dexamethasone (Dexa) from the hydrolyzable Dexa-CB[6]. dexa-cb 199-206 transforming growth factor beta 3 Homo sapiens 104-136 24605794-4 2014 In addition, the differentiation of hMSCs was temporally controlled by changing the release profiles of transforming growth factor-beta3 (TGF-beta3) and/or dexamethasone (Dexa) from the hydrolyzable Dexa-CB[6]. dexa-cb 199-206 transforming growth factor beta 3 Homo sapiens 138-147 24550481-6 2014 We then demonstrated that scaffold-mediated gene delivery of transforming growth factor beta3 (TGF-beta3), using a 3D woven poly(epsilon-caprolactone) scaffold, induced robust cartilaginous ECM formation by hMSCs. polycaprolactone 124-150 transforming growth factor beta 3 Homo sapiens 61-93 24550481-6 2014 We then demonstrated that scaffold-mediated gene delivery of transforming growth factor beta3 (TGF-beta3), using a 3D woven poly(epsilon-caprolactone) scaffold, induced robust cartilaginous ECM formation by hMSCs. polycaprolactone 124-150 transforming growth factor beta 3 Homo sapiens 95-104 24397989-4 2014 In the current study, a co-delivery system based on TGF-beta3-loaded RGD-coupled alginate microspheres was developed for encapsulating periodontal ligament stem cells (PDLSCs) or gingival mesenchymal stem cells (GMSCs). Alginates 81-89 transforming growth factor beta 3 Homo sapiens 52-61 24397989-11 2014 PDLSCs and GMSCs encapsulated in TGF-beta3-loaded RGD-modified alginate microspheres are promising candidates for tendon regeneration. Alginates 63-71 transforming growth factor beta 3 Homo sapiens 33-42 24260594-4 2013 Naringenin, as well as E2 and genistein, was found to modulate the transcription of pS2 and TGFbeta3 in T47D-KBluc cells through an estrogen receptor-dependent mechanism. naringenin 0-10 transforming growth factor beta 3 Homo sapiens 92-100 24018042-3 2013 In wing mesenchymal cells, up-expression of miR-101 by TGF-beta3 treatment is targeting DNMT-3B and thereby altered the methylation of integrin-alpha1 addressed as a positive regulator of endochondral ossification in this study. mir-101 44-51 transforming growth factor beta 3 Homo sapiens 55-64 23839780-10 2013 In the culture with SB216763 + TGF-beta3, significantly more GAG was deposited (P < 0.05). Glycosaminoglycans 61-64 transforming growth factor beta 3 Homo sapiens 31-40 32481828-2 2013 Agarose hydrogels were first seeded with FPSCs at different seeding densities and maintained in a chondrogenic media supplemented with TGF-beta3. Sepharose 0-7 transforming growth factor beta 3 Homo sapiens 135-144 23474328-8 2013 Immunohistochemistry for TGFbeta3/DPSC constructs (n = 5/group) showed cartilage-like matrix formation with glycosaminoglycans. Glycosaminoglycans 108-126 transforming growth factor beta 3 Homo sapiens 25-33 23614294-7 2013 The aim of this study was to examine the effect of IP6 on the expression of genes encoding TGF-beta1, TGF-beta2, TGF-beta3 isoforms and their receptors TbetaRI, TbetaRII, TbetaRIII in human colorectal cancer cell line Caco-2. Phytic Acid 51-54 transforming growth factor beta 3 Homo sapiens 113-122 23579467-9 2013 Glycosaminoglycans contents were increased 217% by TGF-beta3 and 220% by BMP-6. Glycosaminoglycans 0-18 transforming growth factor beta 3 Homo sapiens 51-60 22795539-3 2012 The fabrication of the polyplexed SOX9 genes plus heparinized TGF-beta 3 and their subsequent coating onto dexamethsone loaded PLGA microspheres represents a method for functionalization of the polymeric matrix. dexamethsone 107-119 transforming growth factor beta 3 Homo sapiens 62-72 22678424-8 2013 TGFbeta3 caused a significant increase in pAKT(ser473) in PC3 cells and PI3-kinase inhibitor LY294002 blocked TGFbeta3 induced migration, invasion and phosphorylation of AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 transforming growth factor beta 3 Homo sapiens 0-8 22678424-8 2013 TGFbeta3 caused a significant increase in pAKT(ser473) in PC3 cells and PI3-kinase inhibitor LY294002 blocked TGFbeta3 induced migration, invasion and phosphorylation of AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 transforming growth factor beta 3 Homo sapiens 110-118 22795539-0 2012 SOX9 gene plus heparinized TGF-beta 3 coated dexamethasone loaded PLGA microspheres for inducement of chondrogenesis of hMSCs. Dexamethasone 45-58 transforming growth factor beta 3 Homo sapiens 27-37 22795539-4 2012 The use of SOX9 gene plus heparinized TGF-beta 3 coated dexamethsone loaded PLGA microspheres was evaluated to determine their potential as both gene carriers and cell delivery vehicle. dexamethsone 56-68 transforming growth factor beta 3 Homo sapiens 38-48 22795539-5 2012 By adhesion of hMSCs onto SOX9 gene plus heparinized TGF-beta 3 coated dexamethsone loaded PLGA microspheres, the chondrogenesis-related specific genes of collagen type II were increased 30 times comparing to control. dexamethsone 71-83 transforming growth factor beta 3 Homo sapiens 53-63 22795539-6 2012 Also, the specific extracellular matrix of glycosaminoglycan (GAG) production of hMSCs adhered onto SOX9 gene plus heparinized TGF-beta 3 coated dexamethasone loaded PLGA microspheres increased more 2.5 times than control group. Glycosaminoglycans 43-60 transforming growth factor beta 3 Homo sapiens 127-137 22795539-6 2012 Also, the specific extracellular matrix of glycosaminoglycan (GAG) production of hMSCs adhered onto SOX9 gene plus heparinized TGF-beta 3 coated dexamethasone loaded PLGA microspheres increased more 2.5 times than control group. Glycosaminoglycans 62-65 transforming growth factor beta 3 Homo sapiens 127-137 22795539-6 2012 Also, the specific extracellular matrix of glycosaminoglycan (GAG) production of hMSCs adhered onto SOX9 gene plus heparinized TGF-beta 3 coated dexamethasone loaded PLGA microspheres increased more 2.5 times than control group. Dexamethasone 145-158 transforming growth factor beta 3 Homo sapiens 127-137 22658158-0 2012 Transient exposure to TGF-beta3 improves the functional chondrogenesis of MSC-laden hyaluronic acid hydrogels. Hyaluronic Acid 84-99 transforming growth factor beta 3 Homo sapiens 22-31 23157910-2 2012 METHODS: The human tenocytes were cultured in alpha-MEM media by adding FBS at various concentrations and supplementing both insulin-like growth factor 1 (IGF-1) and transforming growth factor beta-3 (TGFbeta-3). alpha minimal essential medium 46-55 transforming growth factor beta 3 Homo sapiens 166-199 22579131-0 2012 2-Methoxyestradiol causes functional repression of transforming growth factor beta3 signaling by ameliorating Smad and non-Smad signaling pathways in immortalized uterine fibroid cells. 2-Methoxyestradiol 0-18 transforming growth factor beta 3 Homo sapiens 51-83 22579131-1 2012 OBJECTIVE: To investigate the effects and the mechanism of action of 2-methoxyestradiol (2ME(2)) on transforming growth factor (TGF) beta3-induced profibrotic response in immortalized human uterine fibroid smooth muscle (huLM) cells. 2-Methoxyestradiol 69-87 transforming growth factor beta 3 Homo sapiens 100-138 22579131-1 2012 OBJECTIVE: To investigate the effects and the mechanism of action of 2-methoxyestradiol (2ME(2)) on transforming growth factor (TGF) beta3-induced profibrotic response in immortalized human uterine fibroid smooth muscle (huLM) cells. Mercaptoethanol 89-92 transforming growth factor beta 3 Homo sapiens 100-138 22674391-6 2012 Moreover, human extravillous trophoblast cells exposed to 1% oxygen demonstrated increased expression of transforming growth factor-beta3 (TGFB3), and recombinant human TGFB3 inhibited the invasion of human extravillous trophoblast cells in a dose-dependent manner. Oxygen 61-67 transforming growth factor beta 3 Homo sapiens 105-137 22674391-6 2012 Moreover, human extravillous trophoblast cells exposed to 1% oxygen demonstrated increased expression of transforming growth factor-beta3 (TGFB3), and recombinant human TGFB3 inhibited the invasion of human extravillous trophoblast cells in a dose-dependent manner. Oxygen 61-67 transforming growth factor beta 3 Homo sapiens 139-144 22746668-2 2012 A photopolymerizable N-methacrylate glycol chitosan (MGC) was employed to form an in situ gel used to encapsulate microspheres loaded with bone morphogenetic protein 6 (BMP-6) and transforming growth factor-beta3 (TGF-beta3) with human ASCs. n-methacrylate glycol chitosan 21-51 transforming growth factor beta 3 Homo sapiens 180-212 22746668-2 2012 A photopolymerizable N-methacrylate glycol chitosan (MGC) was employed to form an in situ gel used to encapsulate microspheres loaded with bone morphogenetic protein 6 (BMP-6) and transforming growth factor-beta3 (TGF-beta3) with human ASCs. n-methacrylate glycol chitosan 21-51 transforming growth factor beta 3 Homo sapiens 214-223 22421544-2 2012 Studies were performed on three protein drugs: salmon calcitonin (sCT), starch-peptide conjugate, and transforming growth factor-beta3 (TGF-beta3) adsorbed onto solid granules of tricalcium phosphate (TCP). tricalcium phosphate 179-199 transforming growth factor beta 3 Homo sapiens 102-134 22421544-2 2012 Studies were performed on three protein drugs: salmon calcitonin (sCT), starch-peptide conjugate, and transforming growth factor-beta3 (TGF-beta3) adsorbed onto solid granules of tricalcium phosphate (TCP). tricalcium phosphate 179-199 transforming growth factor beta 3 Homo sapiens 136-145 22701102-2 2012 Coral-derived calcium carbonate fully converted (100%) and partially converted to 5 and 13% hydroxyapatite/calcium carbonate (5 and 13% HA/CC) pre-loaded with 125 and 250 mug hTGF-beta(3), and 1:5 and 5:1 binary applications of hTGF-beta(3): hOP-1 by weight, were implanted in the rectus abdominis and harvested on day 20 and 30, respectively, to monitor spatial/temporal morphogenesis by high doses of hTGF-beta(3). Calcium Carbonate 14-31 transforming growth factor beta 3 Homo sapiens 228-240 22701102-2 2012 Coral-derived calcium carbonate fully converted (100%) and partially converted to 5 and 13% hydroxyapatite/calcium carbonate (5 and 13% HA/CC) pre-loaded with 125 and 250 mug hTGF-beta(3), and 1:5 and 5:1 binary applications of hTGF-beta(3): hOP-1 by weight, were implanted in the rectus abdominis and harvested on day 20 and 30, respectively, to monitor spatial/temporal morphogenesis by high doses of hTGF-beta(3). Calcium Carbonate 14-31 transforming growth factor beta 3 Homo sapiens 228-240 22421544-6 2012 UVRR spectroscopy was then used to characterize a protein, TGF-beta3, adsorbed onto solid granules of TCP at 50 and 250 mug/cm(3). tricalcium phosphate 102-105 transforming growth factor beta 3 Homo sapiens 59-68 21866573-4 2012 TGFbeta3 + Dex stimulated degenerated human NP cells to proliferate and exhibit an anti-catabolic gene expression profile (with a decrease in ADAMTS5 and MMP1 compared to basal, and an increase in SOX9, decrease in ADAMTS5, MMP1, collagen I and collagen III compared to day 0), while NCA stimulated the greatest GAG per cell. Dexamethasone 11-14 transforming growth factor beta 3 Homo sapiens 0-8 22369552-3 2012 RESULTS: Active TGF-beta3 protein added to monolayers of cultured oral epithelial cells initially reduced the permeability to dextran (10 kDa), followed by an increase in permeability. Dextrans 126-133 transforming growth factor beta 3 Homo sapiens 16-25 22369552-6 2012 To confirm that TGF-beta3 plays a role in epithelial barrier function, a selective Src family kinase inhibitor saracatinib (AZD0530) was added to cells treated with active TGF-beta3. saracatinib 111-122 transforming growth factor beta 3 Homo sapiens 16-25 21954917-4 2012 Treatment with the HO-1 inducer CoPP (cobalt protoporphyrin IX) counteracted the stimulatory effects of IL-1beta on IL-6, nitrite, PGE2 (prostaglandin E2), TGF (transforming growth factor) beta2, TGFbeta3 and osteocalcin. cobaltiprotoporphyrin 38-62 transforming growth factor beta 3 Homo sapiens 196-204 21866573-4 2012 TGFbeta3 + Dex stimulated degenerated human NP cells to proliferate and exhibit an anti-catabolic gene expression profile (with a decrease in ADAMTS5 and MMP1 compared to basal, and an increase in SOX9, decrease in ADAMTS5, MMP1, collagen I and collagen III compared to day 0), while NCA stimulated the greatest GAG per cell. Glycosaminoglycans 312-315 transforming growth factor beta 3 Homo sapiens 0-8 21866573-5 2012 We conclude that degenerated human NP cells exhibit regenerative potential, and that an optimal treatment will likely require treatments, such as TGFbeta3 + Dex, which were able to increase cell metabolism and reduce catabolism, as well as treatments with factors found in NC conditioned medium, that were able to produce high amounts of GAG per cell. Glycosaminoglycans 338-341 transforming growth factor beta 3 Homo sapiens 146-154 21870950-4 2011 At 0, 7, 14, and 21 days extracellular matrix (ECM) deposition within MSC-seeded agarose hydrogels due to transforming growth factor-beta3 stimulation was determined biochemically and histologically, and then reverse transcription-polymerase chain reaction was used to examine the effects of dynamic compression on cartilage-matrix-specific gene expression. Sepharose 81-88 transforming growth factor beta 3 Homo sapiens 106-138 22370795-6 2012 At low concentrations of TGF-beta3 (1 ng/mL), HP acted to enhance chondrogenesis of both SDSCs and FPSCs, as evident by a 3-fold increase in Sox9 expression and a significant increase in glycosaminoglycan accumulation. Glycosaminoglycans 187-204 transforming growth factor beta 3 Homo sapiens 25-34 22880017-7 2012 Blockade of TGFbeta type I receptors via SB431542 inhibited the TGFbeta3 effects. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 41-49 transforming growth factor beta 3 Homo sapiens 64-72 21707438-0 2011 Transforming growth factor-beta 3 stimulates cartilage matrix elaboration by human marrow-derived stromal cells encapsulated in photocrosslinked carboxymethylcellulose hydrogels: potential for nucleus pulposus replacement. Carboxymethylcellulose Sodium 145-167 transforming growth factor beta 3 Homo sapiens 0-33 21707438-9 2011 CDM supplemented with TGF-beta3 resulted in significantly higher glycosaminoglycan content (762.69+-220.79 ng/mg wet weight) and type II collagen (COL II) content (6.25+-1.64 ng/mg wet weight) at day 21 compared with untreated samples. Glycosaminoglycans 65-82 transforming growth factor beta 3 Homo sapiens 22-31 21807531-4 2011 The aims of this research were (i) to verify the effects of dose-dependent TGF-beta3 treatment on YY1 and p53 expression, in BPH-1 cell line, human benign prostate hyperplasia, and two prostate cancer cell lines, LNCaP, which is androgen-sensitive, and DU-145, which is androgen-non responsive, (ii) establish a correlation between p53 and YY1 and (iii) determine the expression of a number of important intracellular signalling pathways in TGF-beta3-treated prostate cell lines. du 253-255 transforming growth factor beta 3 Homo sapiens 75-84 21820171-7 2011 These findings show that MSCs respond differently to TGF-beta3 when in a PEG-mus environment due to effects of cell dilution, altered growth factor diffusion and/or cellular interactions with the microspheres. peg-mus 73-80 transforming growth factor beta 3 Homo sapiens 53-62 22433307-8 2011 By 2h of exogenous TGF-beta3 treatment, maximal TGF-beta3 mRNA expression levels (2.796 +- 0.518) of 2.74 fold above control values (1.022 +- 0.038) was reached (P < 0.05). Deuterium 3-5 transforming growth factor beta 3 Homo sapiens 19-28 22333231-11 2011 TGF-beta1 was downregulated to 0.130 +- 0.030 and TGF-beta3 was upregulated to 0.490 +- 0.090 by GnRH-a. gnrh-a 97-103 transforming growth factor beta 3 Homo sapiens 50-59 22433307-8 2011 By 2h of exogenous TGF-beta3 treatment, maximal TGF-beta3 mRNA expression levels (2.796 +- 0.518) of 2.74 fold above control values (1.022 +- 0.038) was reached (P < 0.05). Deuterium 3-5 transforming growth factor beta 3 Homo sapiens 48-57 22433307-12 2011 The expression peak [(0.835 +- 0.027) ng/ml] induction of extracellular secreted TGF-beta3 was at 3h (32.12-fold higher than control [(0.026 +- 0.022) ng/ml], (P < 0.05). Tritium 98-100 transforming growth factor beta 3 Homo sapiens 81-90 21308733-2 2011 In addition, the cAMP-responsive element (CRE) in TGF-beta3 promoter is recognized as an important regulatory site for TGF-beta3 auto-regulation. Cyclic AMP 17-21 transforming growth factor beta 3 Homo sapiens 50-59 21823016-4 2011 pcDNA3.1(+)-hTGF-beta3 was transfected into purified PSCs with the use of linear polyamines. Polyamines 81-91 transforming growth factor beta 3 Homo sapiens 12-22 21652067-0 2011 Enhanced MSC chondrogenesis following delivery of TGF-beta3 from alginate microspheres within hyaluronic acid hydrogels in vitro and in vivo. Alginates 65-73 transforming growth factor beta 3 Homo sapiens 50-59 21652067-0 2011 Enhanced MSC chondrogenesis following delivery of TGF-beta3 from alginate microspheres within hyaluronic acid hydrogels in vitro and in vivo. Hyaluronic Acid 94-109 transforming growth factor beta 3 Homo sapiens 50-59 21652067-3 2011 Here, we investigated the co-encapsulation of TGF-beta3 containing alginate microspheres with human MSCs in hyaluronic acid (HA) hydrogels towards the development of implantable constructs for cartilage repair. Alginates 67-75 transforming growth factor beta 3 Homo sapiens 46-55 21652067-3 2011 Here, we investigated the co-encapsulation of TGF-beta3 containing alginate microspheres with human MSCs in hyaluronic acid (HA) hydrogels towards the development of implantable constructs for cartilage repair. Hyaluronic Acid 108-123 transforming growth factor beta 3 Homo sapiens 46-55 21652067-3 2011 Here, we investigated the co-encapsulation of TGF-beta3 containing alginate microspheres with human MSCs in hyaluronic acid (HA) hydrogels towards the development of implantable constructs for cartilage repair. Hyaluronic Acid 125-127 transforming growth factor beta 3 Homo sapiens 46-55 21652067-4 2011 TGF-beta3 encapsulated in alginate microspheres with nanofilm coatings showed significantly reduced initial burst release compared to uncoated microspheres, with release times extending up to 6 days. Alginates 26-34 transforming growth factor beta 3 Homo sapiens 0-9 21652067-8 2011 To prevent this, the co-delivery of parathyroid hormone-related protein (PTHrP) with TGF-beta3 in alginate microspheres was pursued, resulting in partially reduced calcification. Alginates 98-106 transforming growth factor beta 3 Homo sapiens 85-94 21535357-5 2011 The 13-kDa TGFbeta3 monomer band was more intense than the RuBisCO 15-kDa small subunit on Coomassie blue-stained SDS-PAGE gels. Sodium Dodecyl Sulfate 114-117 transforming growth factor beta 3 Homo sapiens 11-19 21535357-7 2011 TGFbeta3 represented 12% of leaf protein and appeared as monomer, dimer and trimer bands on Western blots of SDS-PAGE gels. Sodium Dodecyl Sulfate 109-112 transforming growth factor beta 3 Homo sapiens 0-8 21535357-9 2011 The TGFbeta3 homodimer and trace amounts of monomer were the only bands visible on silver-stained gels following purification by hydrophobic interaction chromatography and cation exchange chromatography. Silver 83-89 transforming growth factor beta 3 Homo sapiens 4-12 21289245-0 2011 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. Calcitriol 0-24 transforming growth factor beta 3 Homo sapiens 33-42 21289245-3 2011 OBJECTIVE: To examine the effect of 1,25-dihydroxyvitamin D(3) (vitamin D(3)) on TGF-beta3-induced fibrosis-related protein expression in immortalized human uterine leiomyoma (HuLM) cells. 1,25-dihydroxyvitamin D 36-59 transforming growth factor beta 3 Homo sapiens 81-90 21289245-3 2011 OBJECTIVE: To examine the effect of 1,25-dihydroxyvitamin D(3) (vitamin D(3)) on TGF-beta3-induced fibrosis-related protein expression in immortalized human uterine leiomyoma (HuLM) cells. Vitamin D 50-59 transforming growth factor beta 3 Homo sapiens 81-90 21289245-6 2011 Western blots as well as immunofluorescence analyses were used to verify the effect of vitamin D(3) on TGF-beta3-induced Smad activation involved in extracellular matrix protein synthesis and deposition, which ultimately lead to tissue fibrosis. Vitamin D 87-96 transforming growth factor beta 3 Homo sapiens 103-112 21289245-7 2011 RESULTS: We observed that TGF-beta3 induced fibronectin and collagen type 1 protein expression in HuLM cells, and that effect was suppressed by vitamin D(3). Vitamin D 144-153 transforming growth factor beta 3 Homo sapiens 26-35 21308733-2 2011 In addition, the cAMP-responsive element (CRE) in TGF-beta3 promoter is recognized as an important regulatory site for TGF-beta3 auto-regulation. Cyclic AMP 17-21 transforming growth factor beta 3 Homo sapiens 119-128 21289245-8 2011 TGF-beta3 also induced protein expression of plasminogen activator inhibitor-1, an important TGF-beta target, in HuLM cells, which was also inhibited by vitamin D(3). Vitamin D 153-162 transforming growth factor beta 3 Homo sapiens 0-9 21289245-9 2011 Additionally, TGF-beta3 induced phosphorylation of Smad2 as well as nuclear translocation of Smad2 and Smad3 in HuLM cells, whereas vitamin D significantly reduced all these TGF-beta3-mediated effects. Vitamin D 132-141 transforming growth factor beta 3 Homo sapiens 174-183 21308733-4 2011 We used exogenous TGF-beta3 to activate the signal pathway of TGF-beta3 auto-regulation in HSCs, results indicated that exogenous TGF-beta3 could up-regulate the protein and mRNA expressions of TGF-beta3, and provoke the phosphorylation of CREB-1 on Ser-133, besides, it could induce the DNA binding activity of p-CREB-1 and activate TGF-beta3 promoter as well. Serine 250-253 transforming growth factor beta 3 Homo sapiens 18-27 21289245-10 2011 Therefore, our results suggest that vitamin D(3) has consistently reduced TGF-beta3 effects that are involved in the process of fibrosis in human leiomyoma cells. Vitamin D 36-45 transforming growth factor beta 3 Homo sapiens 74-83 21308733-4 2011 We used exogenous TGF-beta3 to activate the signal pathway of TGF-beta3 auto-regulation in HSCs, results indicated that exogenous TGF-beta3 could up-regulate the protein and mRNA expressions of TGF-beta3, and provoke the phosphorylation of CREB-1 on Ser-133, besides, it could induce the DNA binding activity of p-CREB-1 and activate TGF-beta3 promoter as well. Serine 250-253 transforming growth factor beta 3 Homo sapiens 62-71 21308733-4 2011 We used exogenous TGF-beta3 to activate the signal pathway of TGF-beta3 auto-regulation in HSCs, results indicated that exogenous TGF-beta3 could up-regulate the protein and mRNA expressions of TGF-beta3, and provoke the phosphorylation of CREB-1 on Ser-133, besides, it could induce the DNA binding activity of p-CREB-1 and activate TGF-beta3 promoter as well. Serine 250-253 transforming growth factor beta 3 Homo sapiens 62-71 21308733-4 2011 We used exogenous TGF-beta3 to activate the signal pathway of TGF-beta3 auto-regulation in HSCs, results indicated that exogenous TGF-beta3 could up-regulate the protein and mRNA expressions of TGF-beta3, and provoke the phosphorylation of CREB-1 on Ser-133, besides, it could induce the DNA binding activity of p-CREB-1 and activate TGF-beta3 promoter as well. Serine 250-253 transforming growth factor beta 3 Homo sapiens 62-71 21308733-4 2011 We used exogenous TGF-beta3 to activate the signal pathway of TGF-beta3 auto-regulation in HSCs, results indicated that exogenous TGF-beta3 could up-regulate the protein and mRNA expressions of TGF-beta3, and provoke the phosphorylation of CREB-1 on Ser-133, besides, it could induce the DNA binding activity of p-CREB-1 and activate TGF-beta3 promoter as well. Serine 250-253 transforming growth factor beta 3 Homo sapiens 62-71 20875791-2 2010 We used nanosecond of molecular dynamic simulations (MD) with explicit solvent, alone and in presence of urea, to investigate the intermediates resulting from the unfolding process of TGF-beta3 and TGF-beta1. Urea 105-109 transforming growth factor beta 3 Homo sapiens 184-193 20878062-9 2010 P53 staining was decreased, while PCNA and TGFbeta3 staining were increased by indomethacin in tumor areas with high presence of COX-2, which correlated to staining of BAX, TUNEL, Bcl-2, c-jun, p21, p27, p53 and NM23. Indomethacin 79-91 transforming growth factor beta 3 Homo sapiens 43-51 21338351-6 2011 Interestingly, transforming growth factor-beta3 (Tgf beta3) expression in MEE and the tip epithelium of the nasal septum begins just before palatal shelf reorientation and lasts until MES disruption, and several works including targeted disruption of the gene have indicated that the process appears to be regulated mainly by the TGFbeta3-TGFbetaR signaling. 2-(N-morpholino)ethanesulfonic acid 184-187 transforming growth factor beta 3 Homo sapiens 15-47 21338351-6 2011 Interestingly, transforming growth factor-beta3 (Tgf beta3) expression in MEE and the tip epithelium of the nasal septum begins just before palatal shelf reorientation and lasts until MES disruption, and several works including targeted disruption of the gene have indicated that the process appears to be regulated mainly by the TGFbeta3-TGFbetaR signaling. 2-(N-morpholino)ethanesulfonic acid 184-187 transforming growth factor beta 3 Homo sapiens 49-58 20557888-6 2010 In MSC-seeded constructs supplemented with TGF-beta3, GAG and collagen accumulation was higher in low oxygen conditions compared to normoxia. Oxygen 102-108 transforming growth factor beta 3 Homo sapiens 43-52 20205160-0 2010 Continuous supply of TGFbeta3 via adenoviral vector promotes type I collagen and viability of fibroblasts in alginate hydrogel. Alginates 109-117 transforming growth factor beta 3 Homo sapiens 21-29 20736064-9 2010 The TGFbeta inhibitor SB-431542, blocked the phosphorylation of Smad2 and stopped the formation of tendon-like tissue. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 22-31 transforming growth factor beta 3 Homo sapiens 4-11 20650328-7 2010 RESULTS: Low oxygen tension (5%) was observed to promote extracellular matrix (ECM) production by CCs cultured in the absence of TGF-beta3, but was inhibitory in the presence of TGF-beta3. Oxygen 13-19 transforming growth factor beta 3 Homo sapiens 178-187 20650328-8 2010 In contrast, a low oxygen tension enhanced chondrogenesis of IFP constructs in the presence of TGF-beta3, leading to superior mechanical functionality compared to CCs cultured in identical conditions. Oxygen 19-25 transforming growth factor beta 3 Homo sapiens 95-104 20408770-4 2010 When AD-MSC were exposed to TGF-beta3, greater extracellular matrix was formed containing types I and II collagen, keratan sulfate, and decorin. Keratan Sulfate 115-130 transforming growth factor beta 3 Homo sapiens 28-37 20493522-9 2010 Zoledronate-treated macroporous constructs showed limited bone formation and in two specimens bone formation was altogether absent; qRT-PCR showed a prominent reduction of OP-1 gene expression whilst TGF-beta(3) expression was far greater than OP-1. Zoledronic Acid 0-11 transforming growth factor beta 3 Homo sapiens 200-211 20408770-5 2010 Biochemical GAG measurement showed that production was significantly greater in TGF-beta3-treated AD-MSC in 3D culture versus untreated controls (p < 0.05). Glycosaminoglycans 12-15 transforming growth factor beta 3 Homo sapiens 80-89 19622399-4 2010 The results confirmed that these cells were able to differentiate along the chondrogenic lineage when encapsulated in Ca-alginate microcapsules with a mean diameter of 600-700microm and stimulated with TGF-beta3. ca-alginate 118-129 transforming growth factor beta 3 Homo sapiens 202-211 20712893-11 2010 Although each TGF-beta isoform decreased PTEN content in a XIAP- and a Smad-dependent manner, decrease of PTEN levels in response to only one isoform, TGF-beta3, was blocked by PI3-K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 193-201 transforming growth factor beta 3 Homo sapiens 151-160 21090328-7 2010 While compared with the model group, myocardial TGF-beta3 mRNA expression was upregulated considerably in NI-PC 6 group (P < 0.01), rather than in NI-BL17 group (P > 0.05), and myocardial TGF-beta 3 expression in both NI-PC 6 and NI-BL17 groups was upregulated obviously (P < 0.01). ni-bl17 150-157 transforming growth factor beta 3 Homo sapiens 48-57 21090328-7 2010 While compared with the model group, myocardial TGF-beta3 mRNA expression was upregulated considerably in NI-PC 6 group (P < 0.01), rather than in NI-BL17 group (P > 0.05), and myocardial TGF-beta 3 expression in both NI-PC 6 and NI-BL17 groups was upregulated obviously (P < 0.01). ni-bl17 236-243 transforming growth factor beta 3 Homo sapiens 48-57 21090328-8 2010 Comparison between NI-PC 6 and NI-BL17 groups showed that the expression levels of myocardial TGF-beta 3 protein and mRNA were significantly higher in NI-PC 6 group than in NI-BL17 group (P < 0.05). bl17 34-38 transforming growth factor beta 3 Homo sapiens 94-104 21090328-8 2010 Comparison between NI-PC 6 and NI-BL17 groups showed that the expression levels of myocardial TGF-beta 3 protein and mRNA were significantly higher in NI-PC 6 group than in NI-BL17 group (P < 0.05). ni-bl17 31-38 transforming growth factor beta 3 Homo sapiens 94-104 21590868-6 2010 Immunohistology studies demonstrated that hMSCs encapsulated in the hydrogel matrix with 1.0 mM RGD and TGF-beta3 showed enhanced positive staining for aggrecan and type II collagen as compared to that with 5.0 mM RGD and unmodified PEG hydrogels. Polyethylene Glycols 233-236 transforming growth factor beta 3 Homo sapiens 104-113 19432813-8 2010 TGF-beta type I receptor inhibitor LY364947 blocked the up-regulation on TGF-beta(1) and TGF-beta(3) production stimulated by mechanical load, and also blocked the chondrogenesis of hMSCs. Ly-364947 35-43 transforming growth factor beta 3 Homo sapiens 89-99 20083094-9 2010 CONCLUSION: The present results demonstrated that the TGF-beta3 rs3917187 polymorphism was associated with left ventricular structure, and had an interactive influence with alcohol on LVESD and LVFSH in hypertensive subjects. Alcohols 173-180 transforming growth factor beta 3 Homo sapiens 54-63 20408761-5 2010 The polymorphism of TGFbeta3 C641A participates in interaction effect for CL/P with environmental exposures, although the polymorphism was not associated with CL/P in single-locus analysis, and synergistic effect of TGFbeta3 C641A and maternal passive smoking could provide a new tool for identifying high-risk individuals of CL/P and also an additional evidence that CL/P is determined by both genetic and environmental factors. Phosphorus 77-78 transforming growth factor beta 3 Homo sapiens 20-28 20408761-5 2010 The polymorphism of TGFbeta3 C641A participates in interaction effect for CL/P with environmental exposures, although the polymorphism was not associated with CL/P in single-locus analysis, and synergistic effect of TGFbeta3 C641A and maternal passive smoking could provide a new tool for identifying high-risk individuals of CL/P and also an additional evidence that CL/P is determined by both genetic and environmental factors. Phosphorus 77-78 transforming growth factor beta 3 Homo sapiens 216-224 20408761-5 2010 The polymorphism of TGFbeta3 C641A participates in interaction effect for CL/P with environmental exposures, although the polymorphism was not associated with CL/P in single-locus analysis, and synergistic effect of TGFbeta3 C641A and maternal passive smoking could provide a new tool for identifying high-risk individuals of CL/P and also an additional evidence that CL/P is determined by both genetic and environmental factors. Phosphorus 162-163 transforming growth factor beta 3 Homo sapiens 20-28 20408761-5 2010 The polymorphism of TGFbeta3 C641A participates in interaction effect for CL/P with environmental exposures, although the polymorphism was not associated with CL/P in single-locus analysis, and synergistic effect of TGFbeta3 C641A and maternal passive smoking could provide a new tool for identifying high-risk individuals of CL/P and also an additional evidence that CL/P is determined by both genetic and environmental factors. Phosphorus 162-163 transforming growth factor beta 3 Homo sapiens 20-28 20534521-7 2010 TGF-beta3 was shown to activate Cdc42 to its active GTP-bound form. Guanosine Triphosphate 52-55 transforming growth factor beta 3 Homo sapiens 0-9 19426117-5 2009 TGF-beta3 cultured with silk elastin-like polymer scaffold carrier exhibits significantly increased glycosaminoglycan and collagen content. Polymers 42-49 transforming growth factor beta 3 Homo sapiens 0-9 19950204-7 2010 BMP-7 in the presence of TGF-beta3 induced superior chondrocytic proteoglycan accumulation, type II collagen, and SOX9 protein expression in alginate and pellet cultures compared to either factor alone. Alginates 141-149 transforming growth factor beta 3 Homo sapiens 25-34 20204746-3 2010 Sorafenib is a Raf kinase inhibitor and our biochemical and genomic evidence supported the potential involvement of the MAPK cascade system and TGFB3 in PH development and the response to therapy. Sorafenib 0-9 transforming growth factor beta 3 Homo sapiens 144-149 19846930-5 2009 5-FU combined with TGF-beta3 and PGE(2) did not alter their inhibitory effects on IL-2-activated natural killer cell cytotoxicity, but substantially affected increased DNA synthesis of cells cultured in IL-2 and co-cultured with 10 ng/ml TGF-beta3 and 10 microM PGE(2). Fluorouracil 0-4 transforming growth factor beta 3 Homo sapiens 238-247 19846930-6 2009 CONCLUSION: Low 5-FU concentrations increase DNA synthesis in lymphocytes and exert a co-stimulatory activity on TGF-beta3 and PGE(2) modulation of IL-2-activated lymphocytes. Fluorouracil 16-20 transforming growth factor beta 3 Homo sapiens 113-122 19683810-4 2009 The increases in gene expression (Sox9, Aggrecan, fibronectin and collagen II), accumulation of chondrogenic matrices and decrease of collagen X gene expression during TGF-beta3 induction were only observed for those beads containing 10mg/g CBD-RGD initially, with 20.18+/-0.73% of that released in a week. Cannabidiol 241-244 transforming growth factor beta 3 Homo sapiens 168-177 19683810-8 2009 It was concluded that the CBD-RGD-alginate culture system promoted the chondrogenesis of mesenchymal stem cells coordinated with TGF-beta3 induction in an RGD dose-dependent manner. Alginates 34-42 transforming growth factor beta 3 Homo sapiens 129-138 19280636-0 2010 Chondrogenic differentiation of mesenchymal stem cells embedded in a scaffold by long-term release of TGF-beta 3 complexed with chondroitin sulfate. Chondroitin Sulfates 128-147 transforming growth factor beta 3 Homo sapiens 102-112 19280636-2 2010 To determine the optimal conditions for chondrogenesis of the embedded rMSCs, transforming growth factor-beta 3 (TGF-beta 3) was physically conjugated with chondroitin sulfate (CS) and mixed into scaffolds, which were subsequently evaluated for the differentiation of transplanted rMSCs. Chondroitin Sulfates 156-175 transforming growth factor beta 3 Homo sapiens 78-111 19280636-2 2010 To determine the optimal conditions for chondrogenesis of the embedded rMSCs, transforming growth factor-beta 3 (TGF-beta 3) was physically conjugated with chondroitin sulfate (CS) and mixed into scaffolds, which were subsequently evaluated for the differentiation of transplanted rMSCs. Chondroitin Sulfates 156-175 transforming growth factor beta 3 Homo sapiens 113-123 19280636-2 2010 To determine the optimal conditions for chondrogenesis of the embedded rMSCs, transforming growth factor-beta 3 (TGF-beta 3) was physically conjugated with chondroitin sulfate (CS) and mixed into scaffolds, which were subsequently evaluated for the differentiation of transplanted rMSCs. Chondroitin Sulfates 177-179 transforming growth factor beta 3 Homo sapiens 78-111 19280636-2 2010 To determine the optimal conditions for chondrogenesis of the embedded rMSCs, transforming growth factor-beta 3 (TGF-beta 3) was physically conjugated with chondroitin sulfate (CS) and mixed into scaffolds, which were subsequently evaluated for the differentiation of transplanted rMSCs. Chondroitin Sulfates 177-179 transforming growth factor beta 3 Homo sapiens 113-123 19280636-4 2010 The results of several different analyses of the transplanted rMSCs embedded in the scaffolds showed that rMSCs coupled with a CS-bound TGF-beta 3 encapsulated scaffold evidenced superior cartilage tissue formation as measured by an assay of specific gene and protein expression. Chondroitin Sulfates 127-129 transforming growth factor beta 3 Homo sapiens 136-146 19280636-6 2010 These results indicate that the elastic block copolymer scaffolds combined with a CS-bound TGF-beta 3 should prove very suitable matrix for cell-based cartilage tissue engineering. Chondroitin Sulfates 82-84 transforming growth factor beta 3 Homo sapiens 91-101 19700613-11 2009 Neutralizing TGF-beta3 antibody decreased the expression of the GAG-rich versican variants 2 to 8 fold in leiomyoma cells. Glycosaminoglycans 64-67 transforming growth factor beta 3 Homo sapiens 13-22 19846930-0 2009 Effects of 5-FU on DNA synthesis and cytotoxicity of human lymphocytes induced by IL-2, TGF-beta3 and PGE2. Fluorouracil 11-15 transforming growth factor beta 3 Homo sapiens 88-97 19846930-2 2009 MATERIALS AND METHODS: We explored 2.5 microM 5-FU-induced DNA synthesis by testing 5-FU activity in hypoxanthine-aminopterin-thymidine (HAT)-containing medium, and its effect on thymidylate synthase (TS) activity and CD25 expression in interleukin (IL)-2-activated human peripheral blood mononuclear cells (PBMCs) and the combined effects with prostaglandin E(2) (PGE(2)) and transforming growth factor (TGF)-beta3. Fluorouracil 46-50 transforming growth factor beta 3 Homo sapiens 377-415 19562724-9 2009 GSEA analysis revealed that FOXF2 up-regulated genes were down-regulated in the same PrSC cells treated with transforming growth factor 3 (TGFbeta3). gsea 0-4 transforming growth factor beta 3 Homo sapiens 139-147 19426117-5 2009 TGF-beta3 cultured with silk elastin-like polymer scaffold carrier exhibits significantly increased glycosaminoglycan and collagen content. Glycosaminoglycans 100-117 transforming growth factor beta 3 Homo sapiens 0-9 18950289-0 2009 BMP-2 enhances TGF-beta3-mediated chondrogenic differentiation of human bone marrow multipotent mesenchymal stromal cells in alginate bead culture. Alginates 125-133 transforming growth factor beta 3 Homo sapiens 15-24 18950289-2 2009 Human BM MSCs encapsulated in alginate beads were induced to differentiate in serum-free medium containing BMP-2 and TGF-beta3. Alginates 30-38 transforming growth factor beta 3 Homo sapiens 117-126 18950289-9 2009 The combination of BMP-2 and TGF-beta3 in alginate culture is superior to the standard differentiation method using TGF-beta alone. Alginates 42-50 transforming growth factor beta 3 Homo sapiens 29-38 18950289-9 2009 The combination of BMP-2 and TGF-beta3 in alginate culture is superior to the standard differentiation method using TGF-beta alone. Alginates 42-50 transforming growth factor beta 3 Homo sapiens 29-37 19103189-10 2009 Treatment of cells with phenylarsine oxide (PAO) at 10 microM that blocks clathrin-mediated endocytosis was shown to inhibit the TGF-beta3-induced protein internalization. oxophenylarsine 24-42 transforming growth factor beta 3 Homo sapiens 129-138 18982456-6 2009 When TGF-beta3 gene expression in astrocytes preparations was inhibited by its antisense oligonucleotide, the induction of DA neurons decreased to a similar level among these three astrocytes preparations. Oligonucleotides 89-104 transforming growth factor beta 3 Homo sapiens 5-14 19103189-10 2009 Treatment of cells with phenylarsine oxide (PAO) at 10 microM that blocks clathrin-mediated endocytosis was shown to inhibit the TGF-beta3-induced protein internalization. oxophenylarsine 44-47 transforming growth factor beta 3 Homo sapiens 129-138 17537129-4 2007 TGFbeta3 was encapsulated in poly(DL-lactic-co-glycolic acid) (PLGA) microspheres and released via controlled delivery in the osteogenic culture of hMSCs and hMSC-derived osteoblasts for up to 28 days. Polyglactin 910 29-61 transforming growth factor beta 3 Homo sapiens 0-8 18454697-8 2009 The combination of the growth factors BMP-4 + TGF-beta 3 with the fibrochondrocyte coculture led to an increase in cell proliferation and GAG production compared to either treatment alone. Glycosaminoglycans 138-141 transforming growth factor beta 3 Homo sapiens 46-56 18587733-10 2008 AmA-HSA-Glu 3.86% and 1.36% stimulated ASMA and TGF-b3 synthesis which were significantly higher than AmA-HSA-Ico (p<0.001 and p<0.01, respectively). Glucose 8-11 transforming growth factor beta 3 Homo sapiens 48-54 18293167-10 2008 In further multivariate regression analysis, only in men, TGF-beta1 and TGF-beta3 genotypes as independent predictors had statistically significant effect on serum creatinine (p = 0.007) and urinary albumin excretion (p = 0.022), respectively. Creatinine 164-174 transforming growth factor beta 3 Homo sapiens 72-81 18272045-11 2008 RT-PCR analysis revealed that 10(-7) mol/L rosiglitazone significantly affected the gene expression at 72-hour: PPAR-gamma mRNA expression was up-regulated and TGF-beta3 mRNA was down-regulated and rosiglitazone at the concentration of 10(-7) mol/L affected these most effectively (P < 0.01). Rosiglitazone 43-56 transforming growth factor beta 3 Homo sapiens 160-169 18272045-12 2008 Immunofluorescence staining demonstrated that treatment with 10(-7) mol/L rosiglitazone resulted in the significant changes of PPAR-gamma and TGF-beta3 protein expressions compared with the other treatment groups and the control group at 72-hour (P < 0.01). Rosiglitazone 74-87 transforming growth factor beta 3 Homo sapiens 142-151 18272045-14 2008 CONCLUSIONS: The present study demonstrates that the PPAR-gamma activator, rosiglitazone, inhibits the cell proliferation partly through the regulations of PPAR-gamma and TGF-beta3 expressions. Rosiglitazone 75-88 transforming growth factor beta 3 Homo sapiens 171-180 18156205-5 2008 Moreover, addition of TGF-beta 3 to villous explants under low oxygen conditions increased the expression of endoglin compared to nontreated explants whereas addition of TGF-beta 3-neutralizing antibodies inhibited the low oxygen stimulatory effect on endoglin expression. Oxygen 63-69 transforming growth factor beta 3 Homo sapiens 22-32 18156205-5 2008 Moreover, addition of TGF-beta 3 to villous explants under low oxygen conditions increased the expression of endoglin compared to nontreated explants whereas addition of TGF-beta 3-neutralizing antibodies inhibited the low oxygen stimulatory effect on endoglin expression. Oxygen 223-229 transforming growth factor beta 3 Homo sapiens 170-180 18156205-7 2008 These data demonstrate that oxygen regulates the placental expression of endoglin via TGF-beta 3. Oxygen 28-34 transforming growth factor beta 3 Homo sapiens 86-96 17673669-6 2007 Furthermore, induction of Wnt/beta-catenin signaling by LiCl enhances chondrogenesis in pericyte pellet cultures in the presence of transforming growth factor-beta3, as demonstrated by increased Sox-9 expression and glycosaminoglycan accumulation into the matrix. Lithium Chloride 56-60 transforming growth factor beta 3 Homo sapiens 132-164 18482449-11 2008 SNPs in six genes (ADD2, ATP6V1B1, PRKAR2B, SLC17A2, SLC22A3, and TGFB3) were also influencing triglycerides, C-reactive protein, homocysteine, and lipoprotein(a) levels. Triglycerides 95-108 transforming growth factor beta 3 Homo sapiens 66-71 18482449-11 2008 SNPs in six genes (ADD2, ATP6V1B1, PRKAR2B, SLC17A2, SLC22A3, and TGFB3) were also influencing triglycerides, C-reactive protein, homocysteine, and lipoprotein(a) levels. Homocysteine 130-142 transforming growth factor beta 3 Homo sapiens 66-71 18039789-9 2008 In presence of ovarian steroids, MAPK inhibitors (p38 and ERK pathways) stimulated TGF-beta3 but inhibited TGF-beta2 expression. Steroids 23-31 transforming growth factor beta 3 Homo sapiens 83-92 17404809-6 2008 By day 28, constructs cultured in the presence of TGF-beta3 exhibited significant increase in sulfated glycosaminoglycan and total collagen content up to 65 and 300%, respectively. Glycosaminoglycans 103-120 transforming growth factor beta 3 Homo sapiens 50-59 16095599-7 2006 Real-time RT-PCR analysis demonstrated that paricalcitol dose- and time-dependently regulated the expression of IGF1, WT1 and TGFbeta3, three genes known to modulate cell proliferation. paricalcitol 44-56 transforming growth factor beta 3 Homo sapiens 126-134 16837067-10 2006 CONCLUSIONS: TGFbeta3 is decreasingly expressed in GL of unaffected CL+/-P and CPO patients and thus further strength is given to a pathogenetic role of TGFbeta3 in the onset of clefts. gl 51-53 transforming growth factor beta 3 Homo sapiens 13-21 16837067-10 2006 CONCLUSIONS: TGFbeta3 is decreasingly expressed in GL of unaffected CL+/-P and CPO patients and thus further strength is given to a pathogenetic role of TGFbeta3 in the onset of clefts. gl 51-53 transforming growth factor beta 3 Homo sapiens 153-161 16837067-10 2006 CONCLUSIONS: TGFbeta3 is decreasingly expressed in GL of unaffected CL+/-P and CPO patients and thus further strength is given to a pathogenetic role of TGFbeta3 in the onset of clefts. cpo 79-82 transforming growth factor beta 3 Homo sapiens 13-21 16820635-5 2006 A cytokine protein array revealed that atorvastatin treatment (100 micromol/L) of human valve ICs caused a downregulation in levels of expression of BMP-2, BMP-6, TGF-beta1, and TGF-beta3 after 24 hours. Atorvastatin 39-51 transforming growth factor beta 3 Homo sapiens 178-187 16613890-7 2006 CONCLUSION: Asoprisnil inhibits the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured leiomyoma cells without affecting their expressions in myometrial cells. asoprisnil 12-22 transforming growth factor beta 3 Homo sapiens 62-70 17066266-8 2007 TGF-beta1 and TGF-beta3 were identified as main regulative factors, due to the finding that steroid hormone inducible TGF-beta1 and TGF-beta3 inhibited cell-cell fusion, whereas antibody-mediated TGF-beta neutralization induced cell-cell fusions. Steroids 92-107 transforming growth factor beta 3 Homo sapiens 14-23 16891311-6 2006 By using mutational analysis in electrophoresis mobility shift assays (EMSAs), we demonstrated that the c-AMP-responsive element (CRE) site in the TGFbeta3 promoter was required for TGFbeta-inducible TGFbeta3 expression. c-amp 104-109 transforming growth factor beta 3 Homo sapiens 147-155 16891311-6 2006 By using mutational analysis in electrophoresis mobility shift assays (EMSAs), we demonstrated that the c-AMP-responsive element (CRE) site in the TGFbeta3 promoter was required for TGFbeta-inducible TGFbeta3 expression. c-amp 104-109 transforming growth factor beta 3 Homo sapiens 200-208 16613890-0 2006 A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. asoprisnil 50-60 transforming growth factor beta 3 Homo sapiens 113-121 16613890-0 2006 A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. asoprisnil 62-66 transforming growth factor beta 3 Homo sapiens 113-121 16697947-18 2006 CONCLUSION: This study focuses on the effects of GnRH-a and tibolone on TGF-beta3 and CTGF expression in myometrium and myomas and supports the hypothesis of a pathogenetic role of these growth factors in uterine fibromatosis. gnrh-a 49-55 transforming growth factor beta 3 Homo sapiens 72-81 16697947-18 2006 CONCLUSION: This study focuses on the effects of GnRH-a and tibolone on TGF-beta3 and CTGF expression in myometrium and myomas and supports the hypothesis of a pathogenetic role of these growth factors in uterine fibromatosis. tibolone 60-68 transforming growth factor beta 3 Homo sapiens 72-81 16736612-3 2006 METHODS: The stable transfection of NIH3T3 fibroblasts with recombinant plasmid expressing hTGFbeta3 was established by using LipofectamineTM2000 and G418 selection. lipofectaminetm2000 126-145 transforming growth factor beta 3 Homo sapiens 91-100 16579687-2 2006 Here, we report microencapsulation of TGFbeta3 in poly-d-l-lactic-co-glycolic acid (PLGA) microspheres and determine its bioactivity. Polylactic Acid-Polyglycolic Acid Copolymer 50-82 transforming growth factor beta 3 Homo sapiens 38-46 16579687-3 2006 The release profiles of PLGA-encapsulated TGFbeta3 with 50:50 and 75:25 PLA:PGA ratios differed throughout the experimental period. Prostaglandins A 76-79 transforming growth factor beta 3 Homo sapiens 42-50 16736612-3 2006 METHODS: The stable transfection of NIH3T3 fibroblasts with recombinant plasmid expressing hTGFbeta3 was established by using LipofectamineTM2000 and G418 selection. antibiotic G 418 150-154 transforming growth factor beta 3 Homo sapiens 91-100 15961560-6 2005 The TGFbeta3-neutralizing antibody and the gap junction inhibitor octanol reduced the effect of TGFbeta3 on the transfer of dye. Octanols 66-73 transforming growth factor beta 3 Homo sapiens 96-104 16355612-2 2005 METHODS: The LEC apoptosis and its related genes expression including bax, fas, TGF-beta 3 mRNA and protein product in tongue fur was determined using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling technique (TUNEL), in situ hybridization, immunohistochemical technique and image analysis. fur 126-129 transforming growth factor beta 3 Homo sapiens 80-90 16355612-2 2005 METHODS: The LEC apoptosis and its related genes expression including bax, fas, TGF-beta 3 mRNA and protein product in tongue fur was determined using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling technique (TUNEL), in situ hybridization, immunohistochemical technique and image analysis. deoxyuridine triphosphate 198-223 transforming growth factor beta 3 Homo sapiens 80-90 17946858-1 2006 In this study, we report that the sequential application of physiologic deformational loading after culturing with the growth factor TGF-beta3 (for 2-3 weeks) yields significantly stiffer chondrocyte-seeded agarose constructs than cultures in which deformational loading was applied during the initial 2-3 week TGF-beta3 exposure period. Sepharose 207-214 transforming growth factor beta 3 Homo sapiens 133-142 16495179-5 2006 In contrast, the expression of TGF-beta(3) mRNA was significantly higher in asiaticoside group (P<0.05). asiaticoside 76-88 transforming growth factor beta 3 Homo sapiens 31-42 15961560-11 2005 The gap-junction inhibitor octanol reduced TGFbeta3-increased levels of bFGF in FS cells. Octanols 27-34 transforming growth factor beta 3 Homo sapiens 43-51 15639641-6 2005 Addition of transforming growth factor beta-3 and insulin like growth factor-1 increased collagen II expression and GAG synthesis in these SOX9 transduced cell pellets. Glycosaminoglycans 116-119 transforming growth factor beta 3 Homo sapiens 12-45 15250049-6 2004 Chondrogenesis induced by TGF-beta3 in alginate bead system was confirmed by examining cartilage specific type II collagen expression and aggrecan, whereas type I collagen expression was not affected by TGF-beta3. Alginates 39-47 transforming growth factor beta 3 Homo sapiens 26-35 15155569-11 2004 Also, introduction of an antisense oligonucleotide for HIF-1 diminishes TGF-beta3 expression during hypoxia, indicating that the up-regulation of TGF-beta3 by hypoxia is mediated through HIF-1. Oligonucleotides 35-50 transforming growth factor beta 3 Homo sapiens 72-81 15155569-11 2004 Also, introduction of an antisense oligonucleotide for HIF-1 diminishes TGF-beta3 expression during hypoxia, indicating that the up-regulation of TGF-beta3 by hypoxia is mediated through HIF-1. Oligonucleotides 35-50 transforming growth factor beta 3 Homo sapiens 146-155 15188132-9 2004 All MCs expressed high levels of membranous beta-catenin, moderate levels of TGF beta 3 and IGFR2, and low levels of FGF-2, with no significant differences seen among the groups. mcs 4-7 transforming growth factor beta 3 Homo sapiens 77-87 15103516-3 2004 Using fibroblast populated collagen gels (FPCGs), exogenous addition of TGF-beta1 or TGF-beta3 was found to increase fibroblast contraction compared to non-treated fibroblasts in serum-free medium, whereas PGE(2) was found to decrease the tendon fibroblast contraction. Prostaglandins E 206-209 transforming growth factor beta 3 Homo sapiens 85-94 15147953-4 2004 The data presented demonstrate that TGFbeta3 enhanced 35SO4 and [3H]thymidine incorporation and inhibited nitrite release after 48 h of culture when compared to unsupplemented constructs. 35so4 54-59 transforming growth factor beta 3 Homo sapiens 36-44 15147953-4 2004 The data presented demonstrate that TGFbeta3 enhanced 35SO4 and [3H]thymidine incorporation and inhibited nitrite release after 48 h of culture when compared to unsupplemented constructs. Tritium 65-67 transforming growth factor beta 3 Homo sapiens 36-44 15147953-4 2004 The data presented demonstrate that TGFbeta3 enhanced 35SO4 and [3H]thymidine incorporation and inhibited nitrite release after 48 h of culture when compared to unsupplemented constructs. Thymidine 68-77 transforming growth factor beta 3 Homo sapiens 36-44 15147953-4 2004 The data presented demonstrate that TGFbeta3 enhanced 35SO4 and [3H]thymidine incorporation and inhibited nitrite release after 48 h of culture when compared to unsupplemented constructs. Nitrites 106-113 transforming growth factor beta 3 Homo sapiens 36-44 12606350-8 2003 Third, and perhaps the most important of all, this TGFbeta3-mediated inhibitory effect on the TJ barrier and the TGFbeta3-induced p-p38 MAP kinase production could be blocked by SB202190, a specific p38 MAP kinase inhibitor, but not U0126, a specific MEK1/2 kinase inhibitor. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 178-186 transforming growth factor beta 3 Homo sapiens 51-59 14734653-2 2004 It was shown that the CdCl(2)-induced disruption of the blood-testis barrier (BTB) associated with a transient induction in testicular TGF-beta2 and TGF-beta3 (but not TGF-beta1) and the phosphorylated p38 mitogen activated protein (MAP) kinase, concomitant with a loss of occludin and zonula occludens-1 (ZO-1) from the BTB site in the seminiferous epithelium. cdcl 22-26 transforming growth factor beta 3 Homo sapiens 149-158 14734653-5 2004 This result clearly illustrates that CdCl(2) mediates its BTB disruptive effects via the TGF-beta3/p38 MAP kinase signaling pathway. Cadmium Chloride 37-44 transforming growth factor beta 3 Homo sapiens 89-98 14734653-10 2004 Additionally, the use of SB202190 to block the TGF-beta3/p-38 MAP kinase pathway also prevented the CdCl(2)-induced loss of cadherin/catenin and nectin/afadin protein complexes from the AJ sites, yet it had no apparent effect on alpha(2)-macroglobulin. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 25-33 transforming growth factor beta 3 Homo sapiens 47-56 14734653-10 2004 Additionally, the use of SB202190 to block the TGF-beta3/p-38 MAP kinase pathway also prevented the CdCl(2)-induced loss of cadherin/catenin and nectin/afadin protein complexes from the AJ sites, yet it had no apparent effect on alpha(2)-macroglobulin. Cadmium Chloride 100-107 transforming growth factor beta 3 Homo sapiens 47-56 12606350-8 2003 Third, and perhaps the most important of all, this TGFbeta3-mediated inhibitory effect on the TJ barrier and the TGFbeta3-induced p-p38 MAP kinase production could be blocked by SB202190, a specific p38 MAP kinase inhibitor, but not U0126, a specific MEK1/2 kinase inhibitor. U 0126 233-238 transforming growth factor beta 3 Homo sapiens 51-59 14605008-1 2004 We have recently shown that TGF-beta3, in the presence of estradiol, increases the release of basic fibroblast growth factor (bFGF) from folliculostellate (FS) cells in the pituitary. Estradiol 58-67 transforming growth factor beta 3 Homo sapiens 28-37 14638551-6 2003 Morphometric analysis 28 days after angioplasty confirmed reduced luminal loss in TGF-beta3 vessels (-0.65+/-0.10 mm2) compared with lacZ (-1.18+/-0.19 mm2) or PBS only (-1.19+/-0.17 mm2; P=0.003). Lead 160-163 transforming growth factor beta 3 Homo sapiens 82-91 12939140-7 2003 Measurements of backbone (15)N relaxation times and interpretation of these by the model-free formalism with axial diffusional anisotropy further reveal significant ms to micros time scale motions centered about two of the conserved disulfide bonds and in several residues that comprise the TGFbeta binding surface. formalism 94-103 transforming growth factor beta 3 Homo sapiens 291-298 12939140-7 2003 Measurements of backbone (15)N relaxation times and interpretation of these by the model-free formalism with axial diffusional anisotropy further reveal significant ms to micros time scale motions centered about two of the conserved disulfide bonds and in several residues that comprise the TGFbeta binding surface. Disulfides 233-242 transforming growth factor beta 3 Homo sapiens 291-298 12606350-8 2003 Third, and perhaps the most important of all, this TGFbeta3-mediated inhibitory effect on the TJ barrier and the TGFbeta3-induced p-p38 MAP kinase production could be blocked by SB202190, a specific p38 MAP kinase inhibitor, but not U0126, a specific MEK1/2 kinase inhibitor. U 0126 233-238 transforming growth factor beta 3 Homo sapiens 113-121 12606350-8 2003 Third, and perhaps the most important of all, this TGFbeta3-mediated inhibitory effect on the TJ barrier and the TGFbeta3-induced p-p38 MAP kinase production could be blocked by SB202190, a specific p38 MAP kinase inhibitor, but not U0126, a specific MEK1/2 kinase inhibitor. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 178-186 transforming growth factor beta 3 Homo sapiens 113-121 12027535-11 2002 TGFbeta3 mRNA level was markedly reduced by LPS alone, or with both L-NMMA and NAC. omega-N-Methylarginine 68-74 transforming growth factor beta 3 Homo sapiens 0-8 12415008-5 2002 LAP-TGFbeta1 and LAP-TGFbeta3 contain the tripeptide sequence, arginine-glycine-aspartic acid (RGD), a known integrin recognition motif. tripeptide K-26 42-52 transforming growth factor beta 3 Homo sapiens 21-29 12415008-5 2002 LAP-TGFbeta1 and LAP-TGFbeta3 contain the tripeptide sequence, arginine-glycine-aspartic acid (RGD), a known integrin recognition motif. arginyl-glycyl-aspartic acid 63-93 transforming growth factor beta 3 Homo sapiens 21-29 12470522-4 2002 The different isoforms of TGFbeta (TGFbeta1, TGFbeta2 and TGFbeta3) and its receptor are all present in both OSE and the underlying ovarian surface stroma. serine O-sulfate 109-112 transforming growth factor beta 3 Homo sapiens 58-66 12027535-11 2002 TGFbeta3 mRNA level was markedly reduced by LPS alone, or with both L-NMMA and NAC. Acetylcysteine 79-82 transforming growth factor beta 3 Homo sapiens 0-8 11978059-7 2002 Using villous explants, we have demonstrated that the oxygen-regulated events of early trophoblast differentiation are in part mediated by TGFbeta(3), an inhibitor of trophoblast differentiation, via HIF-1alpha. Oxygen 54-60 transforming growth factor beta 3 Homo sapiens 139-146 11790723-0 2002 Physiologically low oxygen concentrations in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor-beta3. Oxygen 20-26 transforming growth factor beta 3 Homo sapiens 65-128 11641521-0 2001 Identification of a mutation in the human raloxifene response element of the transforming growth factor-beta 3 gene. Raloxifene Hydrochloride 42-52 transforming growth factor beta 3 Homo sapiens 77-110 11641521-2 2001 Recently raloxifene response element (RRE), a new enhancer with a polypurine sequence for estrogen receptor (ER)-mediated gene activation, was identified on the TGF-beta 3 gene. Raloxifene Hydrochloride 9-19 transforming growth factor beta 3 Homo sapiens 161-171 11641521-2 2001 Recently raloxifene response element (RRE), a new enhancer with a polypurine sequence for estrogen receptor (ER)-mediated gene activation, was identified on the TGF-beta 3 gene. polypurine 66-76 transforming growth factor beta 3 Homo sapiens 161-171 11331657-4 2001 There were gene specific differences, the PS2 and TGFbeta3 genes were about equally sensitive to Zeranol, 17beta-oestradiol and DES whereas a down-regulation of MRG1/p35srj could be detected at fmol/l concentrations of Zeranol whereas 17beta-oestradiol was several orders of magnitude less potent. Zeranol 97-104 transforming growth factor beta 3 Homo sapiens 50-58 11514049-11 2001 Interestingly, TGFbeta3 mRNA levels were significantly higher in freshly isolated OSE than stromal cells. serine O-sulfate 82-85 transforming growth factor beta 3 Homo sapiens 15-23 11331657-4 2001 There were gene specific differences, the PS2 and TGFbeta3 genes were about equally sensitive to Zeranol, 17beta-oestradiol and DES whereas a down-regulation of MRG1/p35srj could be detected at fmol/l concentrations of Zeranol whereas 17beta-oestradiol was several orders of magnitude less potent. Estradiol 106-123 transforming growth factor beta 3 Homo sapiens 50-58 11331657-4 2001 There were gene specific differences, the PS2 and TGFbeta3 genes were about equally sensitive to Zeranol, 17beta-oestradiol and DES whereas a down-regulation of MRG1/p35srj could be detected at fmol/l concentrations of Zeranol whereas 17beta-oestradiol was several orders of magnitude less potent. desacetyluvaricin 128-131 transforming growth factor beta 3 Homo sapiens 50-58 11331657-4 2001 There were gene specific differences, the PS2 and TGFbeta3 genes were about equally sensitive to Zeranol, 17beta-oestradiol and DES whereas a down-regulation of MRG1/p35srj could be detected at fmol/l concentrations of Zeranol whereas 17beta-oestradiol was several orders of magnitude less potent. Zeranol 219-226 transforming growth factor beta 3 Homo sapiens 50-58 11331657-4 2001 There were gene specific differences, the PS2 and TGFbeta3 genes were about equally sensitive to Zeranol, 17beta-oestradiol and DES whereas a down-regulation of MRG1/p35srj could be detected at fmol/l concentrations of Zeranol whereas 17beta-oestradiol was several orders of magnitude less potent. Estradiol 235-252 transforming growth factor beta 3 Homo sapiens 50-58 11159847-1 2001 It has been previously observed that the transforming growth factor beta3 (TGFbeta3) gene can be activated by both estradiol (E(2)) and selective estrogen receptor modulators (SERMs) in vivo but that only SERMs have a potent stimulatory effect on the TGFbeta3 promoter in cultured cells. Estradiol 115-124 transforming growth factor beta 3 Homo sapiens 41-73 11327259-6 2001 In addition, treatment with 10 microg/ml doxycycline resulted in 2.2-fold upregulation of transforming growth factor (TGF-beta3) and a significant decrease of interleukin 1alpha (IL-1alpha), IL-1beta, and IL-6 mRNA. Doxycycline 41-52 transforming growth factor beta 3 Homo sapiens 118-127 11264719-3 2001 In this study, the role of this growth factor in oestrogen-induced lactotropic cell proliferation was determined in vitro using oligonucleotide designed to inhibit TGF-beta3 gene expression. Oligonucleotides 128-143 transforming growth factor beta 3 Homo sapiens 164-173 11264719-4 2001 We used the oligonucleotide in an antisense orientation, which is complementary to regions in the TGF-beta3 message. Oligonucleotides 12-27 transforming growth factor beta 3 Homo sapiens 98-107 11264719-8 2001 The growth-inhibitory effect of antisense oligonucleotide was blocked by TGF-beta3 peptide. Oligonucleotides 42-57 transforming growth factor beta 3 Homo sapiens 73-82 11159847-1 2001 It has been previously observed that the transforming growth factor beta3 (TGFbeta3) gene can be activated by both estradiol (E(2)) and selective estrogen receptor modulators (SERMs) in vivo but that only SERMs have a potent stimulatory effect on the TGFbeta3 promoter in cultured cells. Estradiol 115-124 transforming growth factor beta 3 Homo sapiens 75-83 11159847-1 2001 It has been previously observed that the transforming growth factor beta3 (TGFbeta3) gene can be activated by both estradiol (E(2)) and selective estrogen receptor modulators (SERMs) in vivo but that only SERMs have a potent stimulatory effect on the TGFbeta3 promoter in cultured cells. Estradiol 115-124 transforming growth factor beta 3 Homo sapiens 251-259 10831118-9 2000 Significantly, inhibition of TGFbeta3 by antisense oligonucleotides or antibodies restored the invasive capability to the trophoblast cells in pre-eclamptic explants. Oligonucleotides 51-67 transforming growth factor beta 3 Homo sapiens 29-37 11150643-0 2000 Retinoic acid down-regulates VPAC(1) receptors and TGF-beta 3 but up-regulates TGF-beta 2 in lung cancer cells. Tretinoin 0-13 transforming growth factor beta 3 Homo sapiens 51-61 11150643-9 2000 These results suggest that RA may inhibit lung cancer growth by down-regulating VPAC(1) receptor and TGF-beta 3 mRNA but up-regulating TGF-beta 2 mRNA. Tretinoin 27-29 transforming growth factor beta 3 Homo sapiens 101-111 11095982-0 2000 Characterization of C14orf4, a novel intronless human gene containing a polyglutamine repeat, mapped to the ARVD1 critical region. polyglutamine 72-85 transforming growth factor beta 3 Homo sapiens 108-113 10907639-16 2000 We demonstrate that TGF-beta3 exerts a potent suppressive effect on CML cells that is partly mediated by Fas-independent apoptosis. ammonium ferrous sulfate 105-108 transforming growth factor beta 3 Homo sapiens 20-29 10785229-12 2000 CONCLUSION(S): These findings suggest that TGF-beta3 may be mediating the growth-promoting effects of sex steroids on leiomyomas by playing a role in the fibrogenic process and cell proliferation that characterize these tumors. Steroids 106-114 transforming growth factor beta 3 Homo sapiens 43-52 10712429-0 2000 Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3) During early pregnancy, placentation occurs in a relatively hypoxic environment that is essential for appropriate embryonic development. Oxygen 62-68 transforming growth factor beta 3 Homo sapiens 114-121 10712429-9 2000 These data suggest that the oxygen-regulated early events of trophoblast differentiation are in part mediated by TGFbeta(3) through HIF-1 transcription factors. Oxygen 28-34 transforming growth factor beta 3 Homo sapiens 113-123 10811566-8 2000 The potency of nonylphenol was equal to that of genistein when assayed with pS2 and TGFbeta3, but 10- to 100-fold higher/lower with monoamine oxidase A and [alpha]1-antichymotrypsin, respectively. nonylphenol 15-26 transforming growth factor beta 3 Homo sapiens 84-92 10218988-15 1999 Retinoic acid stimulated TGFbeta3 mRNA expression within 24 h and increased expression of TGFbeta1 and TGFbeta2 after 72 h. Retinol increased expression of TGFbeta1 and TGFbeta2 but not TGFbeta3 after 72 h of treatment. Tretinoin 0-13 transforming growth factor beta 3 Homo sapiens 186-194 10723998-0 2000 Sequence-specific 1H and 15N assignment and secondary structure of transforming growth factor beta3. Hydrogen 18-20 transforming growth factor beta 3 Homo sapiens 67-99 10723998-0 2000 Sequence-specific 1H and 15N assignment and secondary structure of transforming growth factor beta3. 15n 25-28 transforming growth factor beta 3 Homo sapiens 67-99 10218988-15 1999 Retinoic acid stimulated TGFbeta3 mRNA expression within 24 h and increased expression of TGFbeta1 and TGFbeta2 after 72 h. Retinol increased expression of TGFbeta1 and TGFbeta2 but not TGFbeta3 after 72 h of treatment. Tretinoin 0-13 transforming growth factor beta 3 Homo sapiens 25-33 10218988-15 1999 Retinoic acid stimulated TGFbeta3 mRNA expression within 24 h and increased expression of TGFbeta1 and TGFbeta2 after 72 h. Retinol increased expression of TGFbeta1 and TGFbeta2 but not TGFbeta3 after 72 h of treatment. Vitamin A 124-131 transforming growth factor beta 3 Homo sapiens 186-194 8980960-3 1996 We used digoxigenin-labelled riboprobes to localize TGF-beta 1 and TGF-beta 3 gene expression in normal adult human and mouse lung. Digoxigenin 8-19 transforming growth factor beta 3 Homo sapiens 67-77 9811345-6 1998 Cells expressing the TGF-beta1, TGF-beta2, or TGF-beta3 transcripts were identified by in situ hybridization with digoxigenin-labeled riboprobes. Digoxigenin 114-125 transforming growth factor beta 3 Homo sapiens 46-55 9671313-7 1998 In contrast, the ability of TGFbeta3 to up-regulate p27Kip1 and p21Cip1 was maintained in ZnCl2-treated control cells. zinc chloride 90-95 transforming growth factor beta 3 Homo sapiens 28-36 12515175-4 1998 As the expression of TGF-beta 3 increased, the level of serum bilirubin ascended and plasmozyme activity was prolonged. Bilirubin 62-71 transforming growth factor beta 3 Homo sapiens 21-31 9175720-2 1997 Previously, TGF-beta3 was shown to protect epithelial cells and hematopoietic cells from cytotoxic damage in vitro and in vivo, and to reduce the severity and duration of oral mucositis induced by 5-fluorouracil (5-FU) in vivo. Fluorouracil 197-211 transforming growth factor beta 3 Homo sapiens 12-21 9175720-2 1997 Previously, TGF-beta3 was shown to protect epithelial cells and hematopoietic cells from cytotoxic damage in vitro and in vivo, and to reduce the severity and duration of oral mucositis induced by 5-fluorouracil (5-FU) in vivo. Fluorouracil 213-217 transforming growth factor beta 3 Homo sapiens 12-21 9175720-4 1997 We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU. Vinblastine 120-131 transforming growth factor beta 3 Homo sapiens 43-52 9175720-4 1997 We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU. Vincristine 133-144 transforming growth factor beta 3 Homo sapiens 43-52 9175720-4 1997 We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU. Etoposide 146-155 transforming growth factor beta 3 Homo sapiens 43-52 9175720-4 1997 We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU. Paclitaxel 157-162 transforming growth factor beta 3 Homo sapiens 43-52 9175720-4 1997 We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU. Cytarabine 164-169 transforming growth factor beta 3 Homo sapiens 43-52 9175720-4 1997 We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU. Methotrexate 171-183 transforming growth factor beta 3 Homo sapiens 43-52 9175720-4 1997 We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU. Fluorouracil 188-192 transforming growth factor beta 3 Homo sapiens 43-52 9175720-7 1997 The effects of TGF-beta3 were reduced for cisplatin and doxorubicin, drugs that are toxic to cells throughout the cell cycle. Cisplatin 42-51 transforming growth factor beta 3 Homo sapiens 15-24 9175720-7 1997 The effects of TGF-beta3 were reduced for cisplatin and doxorubicin, drugs that are toxic to cells throughout the cell cycle. Doxorubicin 56-67 transforming growth factor beta 3 Homo sapiens 15-24 9032448-9 1997 All TGFbeta isoforms stimulated PGE2 synthesis; TGFbeta3 was approximately twice as potent as TGFbeta1 and TGFbeta2, each of which had similar effects. Dinoprostone 32-36 transforming growth factor beta 3 Homo sapiens 48-56 10075659-5 1999 In addition, the aggregation of TGF-beta3 was investigated systematically as a function of pH and salt concentration using a rapid screening method. Salts 98-102 transforming growth factor beta 3 Homo sapiens 32-41 10075659-12 1999 The CD spectra were characterized by an isodichroic point at 209.5 nm indicating a two-state equilibrium between TGF-beta3 dissolved in solution and aggregated TGF-beta3. Cadmium 4-6 transforming growth factor beta 3 Homo sapiens 113-122 10075659-12 1999 The CD spectra were characterized by an isodichroic point at 209.5 nm indicating a two-state equilibrium between TGF-beta3 dissolved in solution and aggregated TGF-beta3. Cadmium 4-6 transforming growth factor beta 3 Homo sapiens 160-169 10075659-19 1999 Aggregation of TGF-beta3 was, furthermore, influenced by the presence of salt. Salts 73-77 transforming growth factor beta 3 Homo sapiens 15-24 10075659-21 1999 Under physiological conditions (pH 7.4, cNaCl = 164 mM) TGF-beta3 has almost the highest tendency to aggregate and will remain in solution only at nanomolar concentrations. cnacl 40-45 transforming growth factor beta 3 Homo sapiens 56-65 9192553-0 1997 Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Fluorouracil 89-103 transforming growth factor beta 3 Homo sapiens 0-33 9192553-5 1997 Administration of topical TGF-beta 3 prior to chemotherapy with 5-fluorouracil (5-FU) significantly reduced the severity of mucositis with respect to time, reduced chemotherapy-associated weight loss and increased survival. Fluorouracil 64-78 transforming growth factor beta 3 Homo sapiens 26-36 9192553-5 1997 Administration of topical TGF-beta 3 prior to chemotherapy with 5-fluorouracil (5-FU) significantly reduced the severity of mucositis with respect to time, reduced chemotherapy-associated weight loss and increased survival. Fluorouracil 80-84 transforming growth factor beta 3 Homo sapiens 26-36 8819159-7 1996 This movement can be correlated with the mutation of Leu 17 to Val and Ala 47 to Pro in TGF-beta 3. Proline 81-84 transforming growth factor beta 3 Homo sapiens 88-98 8713111-5 1996 Upon ligand binding, both TGF-beta 3 and -beta 2 isoforms induce homodimerization of T beta RII-ED, each TGF-beta subunit being able to bind one T beta RII-ED molecule. rii-ed 92-98 transforming growth factor beta 3 Homo sapiens 26-48 8713111-5 1996 Upon ligand binding, both TGF-beta 3 and -beta 2 isoforms induce homodimerization of T beta RII-ED, each TGF-beta subunit being able to bind one T beta RII-ED molecule. rii-ed 152-158 transforming growth factor beta 3 Homo sapiens 26-48 8612550-4 1996 In transient transfection assays, the promoter sequence from -38 to + 110 of the human TGF beta 3 gene, which contains no palindromic estrogen response element, was sufficient to mediate 17 beta-estradiol or raloxifene induced-reporter gene expression in presence of the estrogen receptor. Estradiol 190-204 transforming growth factor beta 3 Homo sapiens 87-97 8612550-4 1996 In transient transfection assays, the promoter sequence from -38 to + 110 of the human TGF beta 3 gene, which contains no palindromic estrogen response element, was sufficient to mediate 17 beta-estradiol or raloxifene induced-reporter gene expression in presence of the estrogen receptor. Raloxifene Hydrochloride 208-218 transforming growth factor beta 3 Homo sapiens 87-97 7568047-1 1995 Glial cell line-derived neurotrophic factor (GDNF) and transforming growth factor beta 3 (TGF-beta 3) are members of the TGF-beta superfamily with high neurotrophic activity on cultured nigral dopamine neurons. Dopamine 193-201 transforming growth factor beta 3 Homo sapiens 55-88 8788200-9 1996 Treatment of endometrial stromal cells with estradiol-17 beta caused an increase in the levels of TGF beta 1 and TGF beta 3 mRNAs. Estradiol 44-61 transforming growth factor beta 3 Homo sapiens 113-123 8601720-6 1996 In the present study, we show that both TGF-beta1 and TGF-beta2, and to a lesser extent TGF-beta3 isoforms block the ability of normal but not psoriatic DMEC to bind lymphocytes. dmec 153-157 transforming growth factor beta 3 Homo sapiens 88-97 7568047-1 1995 Glial cell line-derived neurotrophic factor (GDNF) and transforming growth factor beta 3 (TGF-beta 3) are members of the TGF-beta superfamily with high neurotrophic activity on cultured nigral dopamine neurons. Dopamine 193-201 transforming growth factor beta 3 Homo sapiens 90-100 7568047-1 1995 Glial cell line-derived neurotrophic factor (GDNF) and transforming growth factor beta 3 (TGF-beta 3) are members of the TGF-beta superfamily with high neurotrophic activity on cultured nigral dopamine neurons. Dopamine 193-201 transforming growth factor beta 3 Homo sapiens 90-98 7758992-2 1995 METHODS: In this paper we investigated the antiproliferative activity of TGF-beta 3 on highly purified bone marrow (BM) CD34+ cells and more immature CD34+/4-hydroperoxycyclophosphamide (4-HC) resistant cells. perfosfamide 156-185 transforming growth factor beta 3 Homo sapiens 73-83 7755487-9 1995 The mRNA expression of TGF-beta 1 and TGF-beta 2 was unchanged, whereas the TGF-beta 3 mRNA level was enhanced 2 to 3-fold after TCDD treatment. Polychlorinated Dibenzodioxins 129-133 transforming growth factor beta 3 Homo sapiens 76-86 7758992-2 1995 METHODS: In this paper we investigated the antiproliferative activity of TGF-beta 3 on highly purified bone marrow (BM) CD34+ cells and more immature CD34+/4-hydroperoxycyclophosphamide (4-HC) resistant cells. perfosfamide 187-191 transforming growth factor beta 3 Homo sapiens 73-83 7819129-2 1994 We report here an evaluation of the effects of the potent estrogen, diethylstilbestrol, on the expression of the three mammalian transforming growth factor beta (TGF beta) isoforms, TGF beta 1, TGF beta 2, and TGF beta 3, in both the uterus and the vagina of the prepubescent mouse. Diethylstilbestrol 68-86 transforming growth factor beta 3 Homo sapiens 210-220 8264630-4 1994 Estradiol decreased mRNA levels of both TGF-beta 3 mRNA transcripts to an equivalent degree in estrogen receptor-positive cells. Estradiol 0-9 transforming growth factor beta 3 Homo sapiens 40-50 1493854-0 1992 TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro. perfosfamide 77-106 transforming growth factor beta 3 Homo sapiens 0-10 8143893-2 1993 We have evaluated the regulation of TGF beta 1, TGF beta 2, and TGF beta 3 mRNAs by 17 beta-estradiol (E2) and 4-hydroxytamoxifen (MOH) in estrogen receptor-positive (ER(+)) MCF-7 and estrogen receptor-negative (ER(-)) MDA-MB-231 human breast cancer cells. Estradiol 91-101 transforming growth factor beta 3 Homo sapiens 64-74 8143893-2 1993 We have evaluated the regulation of TGF beta 1, TGF beta 2, and TGF beta 3 mRNAs by 17 beta-estradiol (E2) and 4-hydroxytamoxifen (MOH) in estrogen receptor-positive (ER(+)) MCF-7 and estrogen receptor-negative (ER(-)) MDA-MB-231 human breast cancer cells. hydroxytamoxifen 111-129 transforming growth factor beta 3 Homo sapiens 64-74 1493854-1 1992 In this study we have investigated the ability of transforming growth factor-beta 3 (TGF-beta 3, 1000 pM) to protect hematopoietic bone marrow (BM) progenitor cells from the cytotoxic activity of 4-hydroperoxycyclophosphamide (4-HC, 100 microM) in vitro. perfosfamide 196-225 transforming growth factor beta 3 Homo sapiens 50-83 1493854-1 1992 In this study we have investigated the ability of transforming growth factor-beta 3 (TGF-beta 3, 1000 pM) to protect hematopoietic bone marrow (BM) progenitor cells from the cytotoxic activity of 4-hydroperoxycyclophosphamide (4-HC, 100 microM) in vitro. perfosfamide 196-225 transforming growth factor beta 3 Homo sapiens 85-95 1493854-1 1992 In this study we have investigated the ability of transforming growth factor-beta 3 (TGF-beta 3, 1000 pM) to protect hematopoietic bone marrow (BM) progenitor cells from the cytotoxic activity of 4-hydroperoxycyclophosphamide (4-HC, 100 microM) in vitro. perfosfamide 227-231 transforming growth factor beta 3 Homo sapiens 50-83 1493854-1 1992 In this study we have investigated the ability of transforming growth factor-beta 3 (TGF-beta 3, 1000 pM) to protect hematopoietic bone marrow (BM) progenitor cells from the cytotoxic activity of 4-hydroperoxycyclophosphamide (4-HC, 100 microM) in vitro. perfosfamide 227-231 transforming growth factor beta 3 Homo sapiens 85-95 1834933-8 1991 The inhibitory effect of norethindrone on TGF beta 2 and TGF beta 3 mRNA levels could be blocked by the addition of 10(-7) M 4-hydroxytamoxifen. hydroxytamoxifen 125-143 transforming growth factor beta 3 Homo sapiens 57-67 1406706-9 1992 As in the human TGF-beta 3 promoter, the CRE site showed activation by forskolin, an effect which could be shown by expression of TGF-beta 3 mRNA in cultured chicken and quail cells as well. Colforsin 71-80 transforming growth factor beta 3 Homo sapiens 16-26 1406706-9 1992 As in the human TGF-beta 3 promoter, the CRE site showed activation by forskolin, an effect which could be shown by expression of TGF-beta 3 mRNA in cultured chicken and quail cells as well. Colforsin 71-80 transforming growth factor beta 3 Homo sapiens 130-140 1637553-10 1992 Only the oligonucleotide targeted to TGF-beta 3 was an effective inhibitor of mesenchymal cell formation. Oligonucleotides 9-24 transforming growth factor beta 3 Homo sapiens 37-47 1834933-0 1991 Growth stimulation and differential regulation of transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, and TGF beta 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. Norethindrone 149-162 transforming growth factor beta 3 Homo sapiens 114-124 1834933-10 1991 This is the first report which demonstrates that norethindrone stimulates estrogen-responsive human breast cancer cell growth and inhibits the expression of TGF beta 2 and TGF beta 3 mRNAs. Norethindrone 49-62 transforming growth factor beta 3 Homo sapiens 172-182 1834933-6 1991 The norethindrone-induced growth stimulation was accompanied by a dramatic decrease in TGF beta 2 and TGF beta 3 mRNA levels, whereas the level of TGF beta 1 mRNA was not affected by any of the compounds tested. Norethindrone 4-17 transforming growth factor beta 3 Homo sapiens 102-112 1834933-8 1991 The inhibitory effect of norethindrone on TGF beta 2 and TGF beta 3 mRNA levels could be blocked by the addition of 10(-7) M 4-hydroxytamoxifen. Norethindrone 25-38 transforming growth factor beta 3 Homo sapiens 57-67 34190399-3 2021 We evaluated sustained release of TGF-beta3 by PLGA microspheres encapsulated in methoxy poly(ethylene glycol)-poly(alanine) (mPA) hydrogels and the resulting enhanced chondrogenic effects. monomethoxypolyethylene glycol 81-110 transforming growth factor beta 3 Homo sapiens 34-43 1996351-0 1991 Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor beta 3. Oligodeoxyribonucleotides 114-134 transforming growth factor beta 3 Homo sapiens 138-171 1996351-4 1991 A phosphoramidate-modified oligonucleotide complementary to TGF beta 3 mRNA was capable of inhibiting normal epithelial-mesenchymal transformation by 80%. phosphoramidic acid 2-17 transforming growth factor beta 3 Homo sapiens 60-70 1996351-4 1991 A phosphoramidate-modified oligonucleotide complementary to TGF beta 3 mRNA was capable of inhibiting normal epithelial-mesenchymal transformation by 80%. Oligonucleotides 27-42 transforming growth factor beta 3 Homo sapiens 60-70 34190399-3 2021 We evaluated sustained release of TGF-beta3 by PLGA microspheres encapsulated in methoxy poly(ethylene glycol)-poly(alanine) (mPA) hydrogels and the resulting enhanced chondrogenic effects. polyalanine 111-124 transforming growth factor beta 3 Homo sapiens 34-43 34190399-3 2021 We evaluated sustained release of TGF-beta3 by PLGA microspheres encapsulated in methoxy poly(ethylene glycol)-poly(alanine) (mPA) hydrogels and the resulting enhanced chondrogenic effects. mpa 126-129 transforming growth factor beta 3 Homo sapiens 34-43 34190399-9 2021 The sustained release of TGF-beta3 in this novel hydrogel system could improve biomedical applicability of mPEG-polypeptide scaffolds. monomethoxypolyethylene glycol 107-111 transforming growth factor beta 3 Homo sapiens 25-34 34809976-15 2022 CONCLUSION(S): SAHA treatment inhibits cell proliferation, cell cycle, ECM formation, and TGF-beta3 signaling in HULP cells, suggesting that histone deacetylation may be useful for treatment of UL. Vorinostat 15-19 transforming growth factor beta 3 Homo sapiens 90-99 34916196-0 2021 (Pirfenidone inhibits proliferation of rabbit tenon fibroblasts by down-regulating TGF-beta3 in the TGF-beta/Smad pathway). pirfenidone 1-12 transforming growth factor beta 3 Homo sapiens 83-92 34916196-3 2021 In RTFs treated with pirfenidone at the initial and optimal concentrations, expressions of TGF-beta3, collagen I and collagen III were examined with both immunofluorescence assay and Western blotting, and their mRNA expression levels were detected using RT-PCR. pirfenidone 21-32 transforming growth factor beta 3 Homo sapiens 91-100 34916196-5 2021 In RTFs treated with pirfenidone at the two concentrations for 24 h, both immunofluorescence assay and Western blotting showed significantly lowered protein expressions of TGF-beta3, collagen I and collagen III as compared with those in the control group (P < 0.05). pirfenidone 21-32 transforming growth factor beta 3 Homo sapiens 172-181 34916196-6 2021 The mRNA expressions of TGF-beta3, collagen I and collagen III in the RTFs were also significantly lowered after treatment with pirfenidone at the initial and optimal concentrations (P < 0.05). pirfenidone 128-139 transforming growth factor beta 3 Homo sapiens 24-33 34916196-7 2021 CONCLUSIONS: Pirfenidone concentration-dependently inhibits the proliferation of RTFs possibly by down-regulating the expression of TGF-beta3 in the TGF-beta/Smad pathway. pirfenidone 13-24 transforming growth factor beta 3 Homo sapiens 132-141 34740750-0 2021 HDAC8-inhibitor PCI-34051-induced exosomes inhibit human bronchial smooth muscle cell proliferation via miR-381-3p mediated TGFB3. PCI 34051 16-25 transforming growth factor beta 3 Homo sapiens 124-129 34740750-0 2021 HDAC8-inhibitor PCI-34051-induced exosomes inhibit human bronchial smooth muscle cell proliferation via miR-381-3p mediated TGFB3. mir-381-3p 104-114 transforming growth factor beta 3 Homo sapiens 124-129 34809976-14 2022 TGFbeta3 and MMP9 gene expression was also significantly down-regulated by 10 muM SAHA (TGFbeta3, FC = 0.596; MMP9, FC = 0.677). Vorinostat 82-86 transforming growth factor beta 3 Homo sapiens 0-8 34809976-14 2022 TGFbeta3 and MMP9 gene expression was also significantly down-regulated by 10 muM SAHA (TGFbeta3, FC = 0.596; MMP9, FC = 0.677). Vorinostat 82-86 transforming growth factor beta 3 Homo sapiens 88-96 35573229-13 2022 Under induction of TGF-beta3, PBMSCs/DCBM composites expressed glycosaminoglycan (GAG), and the related gene expression also increased. Glycosaminoglycans 63-80 transforming growth factor beta 3 Homo sapiens 19-28 34284852-9 2021 After 6 months, the levels of IFN-alpha2, IFN-gamma, and TNF-alpha in the PEG-IFN group were significantly higher than those in the ETV group ( P < 0.01), while the levels of IL-6 and TGF-beta3 were significantly lower than those in the ETV group ( P < 0.01). peg-ifn 74-81 transforming growth factor beta 3 Homo sapiens 184-193 35622002-0 2022 Spatially and Temporally Controllable BMP-2 and TGF-beta3 Double Release From Polycaprolactone Fiber Scaffolds via Chitosan-Based Polyelectrolyte Coatings. polycaprolactone 78-94 transforming growth factor beta 3 Homo sapiens 48-57 35622002-2 2022 For this purpose, polycaprolactone fiber mats were coated with tailored chitosan-based nanogels to bind and release the growth factors bone morphogenetic protein 2 (BMP-2) and transforming growth factor-beta3 (TGF-beta3), respectively. polycaprolactone 18-34 transforming growth factor beta 3 Homo sapiens 176-208 35622002-2 2022 For this purpose, polycaprolactone fiber mats were coated with tailored chitosan-based nanogels to bind and release the growth factors bone morphogenetic protein 2 (BMP-2) and transforming growth factor-beta3 (TGF-beta3), respectively. polycaprolactone 18-34 transforming growth factor beta 3 Homo sapiens 210-219 35622002-8 2022 By using a simple, partial immersion-based dip-coating process, it was possible to apply opposing gradients of the growth factors BMP-2 and TGF-beta3. 3,5-diisopropylsalicylic acid 43-46 transforming growth factor beta 3 Homo sapiens 140-149 35573229-13 2022 Under induction of TGF-beta3, PBMSCs/DCBM composites expressed glycosaminoglycan (GAG), and the related gene expression also increased. Glycosaminoglycans 82-85 transforming growth factor beta 3 Homo sapiens 19-28 35581061-1 2022 Addressing osteochondral defects, the objective of current study was to synthesize bilayered hydrogel, where the cartilage layer was formed by alginate (Alg)-polyacrylamide (PAAm) with and without the addition of TGF-beta3 and bone layer by laponite XLS/Alg-PAAm and characterize by in vitro and in vivo experiments. Alginates 153-156 transforming growth factor beta 3 Homo sapiens 213-222 35118811-0 2022 Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-beta3 and Wnt/beta-Catenin pathways. Simvastatin 0-11 transforming growth factor beta 3 Homo sapiens 68-77 35377824-11 2022 To examine the hypothesis that TGF-beta3 is, at least, a part of this autocrine mechanism, we treated hypoxic leiomyoma cells with the HIF-1alpha inhibitor KC7F2 which we discovered to ameliorate the hypoxia-induced TGF-beta3 expression. KC7f2 156-161 transforming growth factor beta 3 Homo sapiens 31-40 35377824-11 2022 To examine the hypothesis that TGF-beta3 is, at least, a part of this autocrine mechanism, we treated hypoxic leiomyoma cells with the HIF-1alpha inhibitor KC7F2 which we discovered to ameliorate the hypoxia-induced TGF-beta3 expression. KC7f2 156-161 transforming growth factor beta 3 Homo sapiens 216-225 34883477-3 2022 To this end alginate sulfate, a sulfated glycosaminoglycan (sGAG) mimic, was used to functionalize porous alginate-based scaffolds and to support the sustained release of transforming growth factor-beta3 (TGF-beta3). alginate sulfate 12-28 transforming growth factor beta 3 Homo sapiens 171-203 34883477-3 2022 To this end alginate sulfate, a sulfated glycosaminoglycan (sGAG) mimic, was used to functionalize porous alginate-based scaffolds and to support the sustained release of transforming growth factor-beta3 (TGF-beta3). alginate sulfate 12-28 transforming growth factor beta 3 Homo sapiens 205-214 34883477-3 2022 To this end alginate sulfate, a sulfated glycosaminoglycan (sGAG) mimic, was used to functionalize porous alginate-based scaffolds and to support the sustained release of transforming growth factor-beta3 (TGF-beta3). Alginates 106-114 transforming growth factor beta 3 Homo sapiens 171-203